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ABSTRACT 
Adulthood obesity is a known risk factor for colorectal cancer (CRC), but little is 
known about the effect of the duration of obesity on CRC risk. 
 
We studied the link between CRC risk and adulthood obesity, using body mass index 
(BMI) and regional weight gain, as proxies for overall and abdominal obesity, 
respectively.  
 
We analyzed all CRC cases (483 men and 373 women) and associated cancer-free 
controls (907 men and 965 women), from the NSW Cancer, Lifestyle and Evaluation 
of Risk Study. BMI was based on self-reported weight and height (kg/m2), at age 20 
and before cancer diagnosis. Regional weight gain during participant's 20s and 30s 
and after age 50 was self-reported. Those with a BMI <25kg/m2 and >25kg/m2 were 
grouped as normal (reference) and overweight/obese, respectively. Regional weight 
gain was grouped as those who reported any weight gain in the abdomen, or in other 
regions versus no weight gain (reference). BMI at age 20 and before diagnosis were 
combined to derive the time course of obesity. We conducted a complete case 
analysis using logistic regression, adjusting for age, socioeconomic factors, alcohol 
intake, smoking status and physical activity, for the sexes separately. 
 
Although not seen in women, CRC risk was raised in men (odds ratio(OR)=1.48; 95% 
confidence interval(CI):1.13,1.93) who were overweight/obese before diagnosis 
compared to men with a normal BMI. Men who also were overweight/obese at age 
20 had the highest CRC risk (OR=1.69;95%CI:1.22,2.34), men who had a normal 
BMI at age 20 had a lower, but still raised, CRC risk (OR=1.39;95%CI:1.04,1.87) 
compared to men with a normal BMI at both ages. Regional weight gain was not a 
CRC risk predictor in men or women. 
 
Health professionals should particularly encourage men to maintain a healthy weight, 
and for men who are overweight/obese at age 20 to monitor their weight during 
adulthood, and lose weight if they can, as early and prolonged exposure to obesity 
increases their CRC risk considerably. 
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BACKGROUND AND LITERATURE REVIEW 
1.1. Colorectal cancer 
 
1.1.1. Pathogenesis and types of colorectal cancer 
Colorectal cancer (CRC) covers cancer in the large intestinal tract ranging from the 
caecum to the rectum (see Figure 1). It is coded as C18-C20 by the International 
Statistical Classification of Diseases and Related Health Problems, Tenth Revision, 
Australian Modification. 
 
Most CRCs begin as non-malignant adenomas or polyps in the wall of the colon or 
rectum. If untreated, they can progress over time, to become malignant and 
eventually metastasize through the wall of the colon or rectum, and to lymph nodes 
and other areas of the body (1).  
 
There are several types of CRC such as adenocarcinomas, squamous cell cancers, 
carcinoid tumors, sarcomas and lymphomas (2). More than 95% of all CRCs are 
classified as adenocarcinomas, which begin in the mucus-secreting glands in the 
lining of the colon or rectum (3). 
 
Figure 1 The regions of the colon and the rectum.  
 
Source: Cancer Research UK, 2015 (4). 
 
 
1.1.2. Global and local trends in colorectal cancer incidence 
CRC is the third most common cancer worldwide, and in 2012 almost 1.4 million 
new cases of CRC were reported worldwide (5). According to the World Cancer 
Research Fund International, it is predicted that by 2035, worldwide this number of 
annual CRC cases will increase to 2.4 million (5).  
 
Over 50% of CRC cases were found in more developed countries (5). The perception 
that CRC is a disease of the high-income countries is supported by the incidence of 
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CRC doubling, at least, in countries that have recently been classified as high-income 
countries, such as Japan, Singapore, and Eastern European countries (6). Figure 2 
demonstrates that CRC incidence is greater in developed regions, such as North 
America, Europe, and Australasia, compared to less developed regions, with the 
highest incidence rate for CRC reported in Australia/New Zealand and the lowest 
rate reported in Western Africa. In high-income countries with high CRC incidence, 
the trends in CRC incidence over the last 20 years has varied. This rate stabilized in 
France and Australia, while it decreased in the USA and this may be explained by the 
increasing uptake of screening and the removal of precancerous lesions (7). 
Compared to CRC incidence rate, CRC mortality rate varies to a lesser degree 
between the regions. Figure 2 also shows that the male to female ratio for both 
incidence and mortality varied little across geographic regions (8).   
 
Figure 2 Estimated colorectal cancer incidence and mortality worldwide in 2012 
 
Source: IARC Cancer Fact Sheets (8). 
 
In Australia, there were 14,958 new CRC cases diagnosed in 2012 and it is estimated 
that in 2016, the number of new CRC cases would be 17,520 (9). CRC incidence was 
higher for males than females. In 2012, the age-standardized incidence rate for males 
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was 70 cases per 100,000 persons, and for females was 50 cases per 100,000 persons. 
In 2016, it is estimated that the age-standardized incidence rate will increase to 74 
cases for males and 51 cases for females per 100,000 persons (9). 
 
Figure 3 shows that the rate of new CRC cases from 1987 to 2008 in New South 
Wales (NSW), one of the states of Australia, has fluctuated between 70 to 80 per 
100,000 population for males. For females, the rate of new CRC cases was lower as 
it varied between 45 and 55 per 100,000 population (10). 
 
Figure 3 Colorectal cancer: new cases and death rated by sex, NSW, 1987 to 2011. 
 
 
Source: HealthStats NSW, 2015 (10). 
 
 
One disability-adjusted life year (DALY) is equivalent to ‘one year of ‘healthy life’ 
lost due to a disease or injury’ and is used to compare the fatal and non-fatal effects 
of various medical conditions (11). A 2011 Australian study found that cancer was 
the leading disease group to cause burden, accounting for 19% of total DALYs lost 
(11). In particular, CRC was ranked 13 amongst the leading causes of total burden in 
both sexes, accounting for 53,084 and 39,338 years of ‘healthy life’ lost in males and 
females, respectively (11). 
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1.1.3. Risk factors for colorectal cancer 
 
1.1.3.1. Age 
In Australia, the age-specific CRC incidence rate increased rapidly from the age of 
50 in 2012 (see Figure 4) (12). Similarly, in the UK, the age-specific CRC incidence 
rate for individuals aged 85-89 years was significantly higher than individuals aged 
50-54 years. During 2011-2013, 68% of new CRC cases in the UK were people aged 
70 years or older (13). Comparably, the majority (90%) of new CRC cases in the 
USA were people aged 50 years or older (14).  
 
Figure 4 Age-specific incidence rates for colorectal cancer, 2012 
 
Note: Rates are expressed per 100,000 males/females 
Source: Australian Institute of Health and Welfare, 2016 (12). 
 
1.1.3.2. Country of birth 
In countries consisting of many ethnic groups, CRC incidence rate has shown to vary 
between ethnic groups. In NSW, 23% of its residents were born overseas. The CRC 
incidence rate for migrants from the most common 25 places of birth was lower or 
similar to the Australian-born population (15). In the UK, the age-standardized rate is 
greater for White males (ranging from 54.1 to 55.3 cases per 100,000 people) than 
Black males (ranging from 29.7 to 43.8 cases per 100,000) and Asian males (ranging 
from 19.1 to 28.0 cases per 100,000). Similarly, White females experienced the 
highest age-standardized rate (ranging from 34.0 to 34.8 per 100,000) while Black 
females (ranging from 20.4 to 31.6 per 100,000) and Asian females (ranging from 
11.3 to 17.5 per 100,000) experienced lower rates (13).  In North America, CRC 
incidence rate is greatest for Black males and females and lowest for Asian/Pacific 
Islander males and females (14). However, studies have shown that the association 
between racial disparity and CRC risk is modest and it indicates socioeconomic 
factors may be responsible for the variation seen for CRC risk (16, 17). An 
Australian study found that Asian and European immigrants were less likely to 
participate in the cancer screening programs compared to Australian-born individuals, 
even after adjusting for socioeconomic factors. This finding suggests that the lower 
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incidence rate in immigrants may be because they are less likely to participate in the 
screening program. This study concludes that programs promoting cancer screening 
to target immigrant groups may be necessary (18). 
 
1.1.3.3. Socioeconomic status 
In cancer epidemiology, socioeconomic status (SES) measures how accessible basic 
resources to attain and sustain good health are for an individual. As the International 
Agency for Research on Cancer (IARC) describes, SES is an abstract concept that is 
approximated through proxy variables such as income, education, and place of 
residence. These variables are not the direct cause of cancer but rather indicate 
exposure to unknown and underlying causes (19).  
 
A 1995 review found that colon cancer risk was lower in individuals with a low SES. 
However, the review found no consistent trend for the association between rectal 
cancer risk and SES (20). A 2010 review examined 21 studies on the association 
between CRC risk and SES, measured by education, occupation, income, poverty or 
a combination of these proxies. It found that this association varied for different 
countries. In North America, low SES was associated with higher incidence of colon 
and rectal cancer compared to high SES. In contrast, in an Australian study and most 
European studies, low SES was linked with lower CRC incidence. The more recent 
review explains that this variation in the association between CRC risk and SES 
between countries may be explained by two factors. Firstly, the link between SES 
and lifestyle risk factors for cancer, such as physical activity and diet, may vary 
between countries. Secondly, the CRC screening rate is different between the 
countries. However, it is suggested that the international variation may change as 
European countries and Australia roll out CRC screening programs (discussed 
further in Section 1.1.3.4.). The author expressed hope that if the screening programs 
encourage the participation of individuals from all SES categories, then the program 
may narrow the SES gap for CRC detection (21). 
 
Accessibility/Remoteness Index of Australia (ARIA plus) 
ARIA plus is an Australian standard measure of remoteness endorsed by the 
Australian Bureau of Statistics. It is an index that measures the road distance 
between a populated locality and a health service center. Populated locality is the 
location from where individuals are traveling from to receive services. ARIA plus 
has five levels of remoteness: Major City of Australia, Inner Regional Australia, 
Outer Regional Australia, Remote Australia and Very Remote Australia (22). Figure 
5 shows the association between the rate of new CRC cases in NSW by remoteness 
and sex, with the three categories Outer Regional, Remote and Very Remote 
Australia combined. In 2008, the rate of new CRC cases was lowest in Major Cities 
for both males (73.0 per 100,000 population) and females (49.8 per 100,000 
population) (23). The highest rate of new CRC cases for males was seen in the 
combined category, Outer Regional and Remote areas (76.9 per 100,000 population), 
while the highest CRC cases for females was seen in the Inner Regional area (55.2 
per 100,000 population) (23). A Queensland study found that amongst CRC patients, 
patients living in Inner and Outer Regional areas were more likely to have been 
diagnosed with advanced CRC compared to patients living in the Major cities 
(p=0.05) (24). 
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Figure 5 Colorectal cancer: new cases by remoteness from health service centers and 
sex, NSW, 2008. 
 
 
Source: HealthStats NSW 2015 (23). 
 
1.1.3.4. Colorectal cancer screening 
In Australia, The National Bowel Cancer Screening Program was launched in August 
2006 with the aim of reducing illness and death through early detection and 
prevention. Screening may reduce CRC incidence through the detection of 
precancerous lesions and their removal (25). In Australia, the current guidelines 
recommend that every two years individuals aged 50 years and older or those with 
family history be screened using the fecal occult blood test, a non-invasive test which 
detects traces of blood in their stool. According to a monitoring report on the 
screening program, from July 2013 to June 2014, 1.4 million Australians aged 50, 55, 
60 or 65 were sent a screening kit. With 36% of kits returned, the 2013-2014 
participation rate had increased compared to the 2012-2013 participation rate 
(33.4%). Of those who returned a valid screening kit, 7.5% had a positive screening 
result, and 49.5% of these individuals recorded to have had received follow-up 
colonoscopy (18,669 individuals). Of those who underwent colonoscopy, a 
significant number were diagnosed with confirmed cancer (149 individuals), 
suspected cancer (599 individuals) and advanced adenoma (1,691 individuals) (26).  
 
In this screening program, males had a lower participation rate (33.6%), compared to 
females (38.5%), but a higher rate of cancer diagnosed through screening (97 males 
and 52 females with confirmed cancer). The participation rate was lower for those 
living in remote (33.0%) and very remote (24.7%) regions, and those in the lowest 
SES (34.1%). A smaller proportion of Aboriginal and Torres Strait Islanders 
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participated in the screening program (0.9%) than the compulsory national census, 
the 2011 Australian Census of Population and Housing (1.5%). Therefore, the 
indigenous population was less inclined to be screened for CRC than expected. 
However, rates of positive screening results increased with increasing geographical 
remoteness, decreasing SES and this rate was higher in indigenous participants 
compared to non-indigenous participants (26).  
 
1.1.3.5. Family history of colorectal cancer 
A 2013 meta-analysis by Johnson et al. pooled results from 16 studies and examined 
the association between history of CRC in first-degree relatives and CRC risk. Six 
studies examined this association in females only and found that individuals with 
positive family history had an increased CRC risk compared with those without 
family history (Relative Risk (RR):1.60, 95% confidence interval (CI): 1.33–1.92). 
Whereas, in studies that included both males and females, the relative risk for CRC 
associated with family history was slightly higher (RR: 1.90, 95% CI: 1.67–2.17). 
The meta-analysis did not find that this difference between studies with females only 
and both sexes was statistically significant (27).  
 
1.1.3.6. Smoking 
IARC is an interdisciplinary agency with the mission of understanding cancer causes 
and works with its parent organization, World Health Organization, to reduce the 
burden of this disease. IARC has confirmed that cigarette smoking is a risk factor for 
CRC. Most of the studies reviewed by IARC used smoking status as a measure of 
cigarette smoking and examined its association with CRC risk. Most of the case-
control studies reviewed by IARC found a non-significant positive association for 
CRC risk in current and former smokers, separately (28). However, IARC reported 
that based on the largest meta-analysis that pooled data from 36 prospective cohort 
studies, current and former smokers had a significant 15% and 20% increased CRC 
risk, respectively, compared to never smokers. The meta-analysis did not find 
evidence of publication bias or heterogeneity (29). Similarly, an Australian case-
control study found that current and former smokers had a non-significant 5% and a 
significant 24% increased CRC risk, respectively, compared to never smokers (30). 
 
1.1.3.7. Alcohol consumption 
In a 2007 publication, World Cancer Research Fund International (WCRF) stated 
that there is convincing evidence that alcohol consumption increases CRC risk in 
males while in females evidence suggests that this association is probable (6). In 
their updated 2010 publication, WCRF pooled results from 12 studies and found that 
one alcoholic drink per day was associated with a non-significant, increased risk of 
CRC (RR: 1.11; 95% CI: 0.90-1.38), colon cancer (RR: 1.16; 95%CI: 0.97-1.39) and 
rectal cancer (RR: 1.11; 95%CI: 0.97-1.29). There was heterogeneity between the 
four CRC studies and five colon cancer studies but not between the three rectal 
cancer studies. There was no evidence of publication bias (31).  
 
Similar to the WCRF 2010 publication, a 2013 meta-analysis by Johnson et al. 
pooled results from 22 studies and found that CRC risk and alcoholic consumption of 
five drinks per week had a positive yet non-significant association (RR: 
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0.91–1.23). This meta-analysis found that the association between alcohol 
consumption and CRC risk did not vary by gender, cancer site and study design (27). 
Also, an Australian case-control study collected data on alcohol consumption 10 
years ago and found that one to seven alcoholic drinks per week was associated with 
non-significant, increased CRC risk (RR: 1.09; 95% CI: 0.83-1.43) (30). 
 
1.1.3.8. Physical activity 
In a 2007 publication, WCRF determined that there is convincing evidence that 
physical activity decreases CRC risk (6). In 2010, WCRF conducted a dose-response 
meta-analysis by pooling results from six studies. It found that total physical activity 
measured by metabolic equivalent of task (MET) hour per day, a measure of energy 
consumption, was associated with decreased risk of CRC (RR: 0.97 per 5 MET hours 
per day, 95% CI: 0.94-0.99) and colon cancer (RR: 0.92 per 5 MET hours per day, 
95% CI: 0.86-0.99) but was not associated with rectal cancer risk (RR: 1.02 per 5 
MET hours per day, 95% CI: 0.95-1.10). There was no publication bias detected in 
the three CRC studies or the three rectal cancer studies but publication bias was 
detected in the five colon cancer studies (31).  
 
Similar to the WCRF findings, Johnson et al. pooled results from 21 studies and 
found that CRC risk and increased physical activity measured by a standardized 
physical activity score had an inverse association (p<0.001) (27).  
 
1.1.3.9. Diet 
A 2013 meta-analysis by Johnson et al. found that the consumption of red meat, and 
low consumption of vegetable and fruit were associated with increased CRC risk 
(27). By pooling results from 14 studies, this meta-analysis found that the 
consumption of five servings of red meat per week compared to no consumption 
increased CRC risk (RR:1.13, 95% CI: 1.09-1.16). The study found no evidence of 
publication bias or small study effect. Johnson et al. examined nine studies and found 
that the consumption of one, two or three servings of fruit per day compared to little 
consumption decreased an individual’s risk of developing CRC by 9%, 15% and 
16%, respectively (RR:0.91, 95% CI:0.85-0.96 for one serving/day; RR:0.85, 95% 
CI: 0.78-0.94 for two servings/day; RR:0.84, 95% CI:0.75-0.96 for three 
servings/day). This study examined the influence on CRC risk of vegetable 
consumption using results from eight studies. It found that an individual’s CRC risk 
decreased by 6% when vegetable consumption per day increased by two servings 
(RR: 0.94, 95% CI: 0.91-0.98). There was some evidence of publication bias or small 
study effect (27). 
 
1.2. Adult height: a measure of early experiences 
From preconception to early adulthood, optimal genetic, environmental, hormonal 
and nutritional support is necessary for growth and attaining adult height. It is 
because of all these factors that adult height is often described as a marker of early 
life experiences. The secular trend for height has been shown to increase over time as 
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populations settle into a secure environment with good population health and socio-
economic conditions. Nutritional support is also necessary, as a child’s diet should 
include sufficient energy and key nutrients such as amino acids, fatty acids and 
vitamins. Nutritional shortage has been related to the stunting of growth. Adoption 
and migrant studies have shown that individuals who move from an environment 
where nutritional food is scarce to an environment where food supplies are sufficient, 
the secular trend for height increases. Also, nutritional style has been related to adult 
attained height. A nutritional style (typically found in tropical Asia) mainly based on 
rice-derived protein was related to very small adult male height while a nutritional 
style (typically found in Northern or Central Europe) mainly based on animal protein 
was related to greater attained male height (32). 
 
1.2.1. Global and local trends for adult height 
An early study from 1976 investigated the secular trends for young adult height in 
several ethnic groups in Asia, Australia, North America and Europe. It utilized data 
gathered from 1834 to 1970. It found in Australia, Belgium, Japan, Norway and the 
United States that on average mean height increased by 0.8cm per decade for young 
female adults aged 17.5 years. From Norway, United States (African American), 
Japan, Canada, Australia and Belgium, the mean height for males at age 14 years 
increased by 3.3cm, 2.1cm 2.0cm, 1.8cm, 1.6cm and 1.1 cm, respectively, per decade 
(33). 
 
A more recent 2007 study investigated the trends for adult height in ten European 
countries. Participants in this study were born between 1950 and 1980. Like the 1976 
study, this study also found that adult height continued to increase in all ten countries. 
When comparing the growth rate of participants in Northern and Southern Europe, 
participants who lived in Southern Europe (Greece, Italy, Portugal, and Spain) 
experienced greater growth compared to those located in Northern Europe (Austria, 
Belgium, Denmark, Finland, Ireland, and Sweden) (34). 
 
An Australian study, published in 2000, investigated the secular trend for adult 
height. This study collected data between 1992 and 1993 of school students who 
were aged 17 years. They compared this data to historical data collected throughout 
the 20th century. Like other international studies, adult height in Australia continued 
to increase during the 20th century by 2.1cm per decade and 1.6cm per decade for 
males and females, respectively. This positive trend for mean adult height was seen 
consistently in the following states, Victoria, New South Wales and Western 
Australia. The growth rate of adult height during the first half of the 20th century 
increased rapidly compared to the last 20 years of the century (35). 
 
1.2.2. Adult height and colorectal cancer incidence 
Studies that explored the association between adult height and the risk of developing 
colon cancer, rectal cancer or CRC were considered (see in detail in Section 5.1.1.). 
 
Most of the studies in our search found that height was associated with increased 
CRC risk for both sexes (see Table 3 in Section 5.1.1.). Similar findings were 
reported in the 2010 WCRF systematic literature review of nine cohort studies. In 
this review, the relative risk of developing CRC was 1.05 (95% CI:1.03-1.08) per 5 
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cm increase in height. This relationship was consistent for both sexes. When 
examining site-specific results, height was associated with colon cancer (OR:1.09; 95% 
CI:1.05-1.12) while the association between height and rectal cancer was non-
significant (OR:1.03; 95% CI:0.99-1.07) (31).  
 
1.3. Body Mass Index: a proxy for general adiposity 
Body mass index (BMI) is the most commonly used, crude measurement of general 
adiposity. BMI can be calculated by weight divided by height squared (kg/m2). The 
World Health Organization recommended BMI cut-off points give four categories: 
underweight (less than 18.50 kg/m2), normal (18.50 kg/m2 to 24.99 kg/m2), 
overweight (25.00 kg/m2 to 29.99 kg/m2) and obese (greater than or equal to 30.00 
kg/m2). BMI is useful in assessing the prevalence of obesity in a population and 
evaluating interventions and identifying individuals at risk of developing cancer. 
 
1.3.1. Global and local trends for obesity 
In 2014, almost two billion adults around the world were overweight or obese (36). 
This equates to 39% of male adults and 40% of female adults overweight worldwide 
and 11% of male adults and 15% of female adults obese (37). 
 
Figure 6 displays the prevalence of obesity in countries worldwide. In some countries 
of North America, North Africa, and West Asia, 30% or more of their adult 
population were obese (shaded dark green). In the remaining countries of North 
America, most of South America, Europe, and Central Asia, some of the countries of 
North and South Africa, and the Oceania region (Australia and New Zealand), 20.0% 
to 29.9% of their population were obese (shaded vibrant green) (38). 
 
Figure 6 Prevalence of obesity, ages 18+, 2014 (age-standardized estimate) both 
sexes 
 
 
Source: World Health Organization (38). 
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In 2011-2012, over 60% of Australians over the age of 18 years were classified as 
overweight or obese. In 2011-2012, the proportion of Australian males (69.7%) who 
were overweight or obese was greater than Australian females (55.7%), but the 
proportion of obese males and females were similar (27.5%). 
 
Data collected for the Australian Bureau of Statistics has also shown that the 
prevalence of obesity has increased over time (see Figure 7). In 1995, 26.1% of 
Australians aged 55-64 were obese. The proportion of Australians in this age range 
who were obese in 2007-2008 was 34.1% and this percentage increased further in 
2011-2012 with 36.7% obese (39). 
 
Figure 7 demonstrates that the prevalence of obesity in Australia continued to rise 
until the age of 64 years, after which it decreased, and this trend is seen at three time 
points (1995, 2007-2008 and 2011-2012). When comparing the trends for these three 
time points, the prevalence of obesity in all age groups increased over time (39). 
 
Figure 7 Persons aged 18 years & over – Proportion who were obese, 1995 to 2011-
12. 
 
Footnote: Based on Body Mass Index for persons whose height and weight was 
measured. 
Source: Australian Health Survey: Updated Results, 2011-12 (39). 
 
 
The data collected by the Australian Bureau of Statistics explored the proportion who 
were overweight or obese during 2011-2012 by remoteness from health service 
centers and sex (Figure 8). In 2011-2012, the proportion of Australians who were 
overweight or obese was lowest in the Major Cities for both males (67.7%) and 
females (52.5%) compared to those who did not reside in the Major Cities (i.e. males 
(74.4%) and females (63.2%) who resided in regional and remote Australia) (39). 
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Figure 8 Persons aged 18 years & over – Proportion who were overweight or obese 
by remoteness by sex, 2011-12. 
 
Footnote: Based on Body Mass Index for persons whose height and weight was 
measured. 
Source: Australian Health Survey: Updated results, 2011-12 (39). 
 
 
1.3.2. Body Mass Index and colorectal cancer incidence 
Studies that explored the association between BMI and the risk of developing colon 
cancer, rectal cancer or CRC were considered (see in detail in Section 5.1.2.). 
 
The majority of the studies from our search (see Table 4 in Section 5.1.2.) found that 
BMI was associated with increased CRC risk for both sexes. Similar findings were 
seen in the 2010 WCRF systematic literature review that identified 24 new studies. 
In this review, the relative risk of developing CRC increased by 2% per unit increase 
in BMI (kg/m2). When examining site-specific results, BMI was associated with both 
colon cancer (3% increased risk per kg/m2) and rectal cancer (1% increased risk per 
kg/m2). For males (3% increased risk per kg/m2) the risk of developing CRC was 
greater than females (2% increased risk per kg/m2) (31). In 2010, it was estimated 
that 3.4% of all cancers were attributed to obesity and this proportion included 1,101 
colon cancer cases (40). 
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1.4. Proxies of obesity: focusing on abdominal obesity 
 
1.4.1. Limitations of Body Mass Index 
Although commonly used as a measure of obesity, BMI has limitations. Firstly, 
individuals with the same BMI do not necessarily have the same body fat and lean 
body mass composition (41, 42). Secondly, Renehan et al. showed that self-reported 
weight underestimates true body weight and the extent of this varies with age and 
gender (43). Although this variation did not alter the risk estimates in the study by 
Renehan et al., in a study by Park et al., self-reported BMI in females was 
significantly associated with CRC risk while measured BMI was not (44). Thirdly, 
those who were heavier were less likely to self-report their height and weight thus 
these at-risk participants would be under-represented in any analysis that included 
BMI (44). Finally, BMI has low sensitivity and classifies over half of the individuals 
as being normal/overweight whom are classified as obese, by another body fat 
measurement (45).  
 
Besides the apparent limitation of BMI, the actual distribution of body fat needs 
further investigation. The 2015 meta-analysis by Karahalios identified the need for 
more studies that elucidate whether the elevated CRC risk is linked with general 
weight gain or abdominal obesity (46). Visceral adipose tissue, approximated by 
measures of abdominal obesity, triggers more metabolic dysfunction, which is linked 
to increased CRC risk compared to subcutaneous adipose tissue (47, 48). In light of 
the limitations of BMI and the strong association between abdominal obesity and 
CRC risk, this study created three proxies of obesity that are related to abdominal as 
well as general obesity, that do not require measurements and can be cheaply and 
easily adapted in the clinical and research setting.  
 
1.4.2. Waist circumference: an existing measurement of abdominal 
adiposity 
 
Studies have tried to determine which of the other anthropometric measurements, 
such as waist circumference, waist to height ratio and waist to hip ratio, is most 
correlated to abdominal obesity. According to a 1996 editorial, waist circumference 
to height ratio had the highest correlation to intra-abdominal fat, while another study 
showed that waist circumference is a better measure (49, 50). More recent studies 
show that waist circumference and waist to hip ratio have performed well in 
predicting colon cancer risk (51, 52). In fact, in Australia, measuring waist 
circumference has become a recommended practice in primary healthcare along with 
measuring weight and height (53). However, waist circumference is limited because 
it can be measured in eight locations according to a 2008 literature review, which 
may lead to inconsistencies in measurement and thus with associated CRC risk (54). 
The iliac crest is a bony structure and because it is minimally affected by body 
changes it is useful when measuring waist circumference. However, waist 
circumference measured at the iliac crest is done with low precision, as it requires 
training, again adding to possible inconsistencies (55). As shown in a study by Park 
et al., self-reported waist circumference was the same as measured waist 
circumference for only 56% of males and females (44). Although accepted as a 
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measure of abdominal adiposity, waist circumference cannot distinguish between 
visceral adipose tissue and subcutaneous adipose tissue, which are separated by the 
muscular wall of the abdomen. Methods that involve an MRI or a CT can accurately 
distinguish between visceral adipose tissue and subcutaneous adipose tissue, 
however, this approach cannot be readily used because of its high cost, low 
availability, trained skill required, significant time required for scanning and 
incompatibility for those who are severely obese (56). Therefore, this study created 
proxies that measure abdominal obesity, weight gain in the waist (WGW) and weight 
gain in the apple region (WGA), due to the absence of economical and effective 
measures of abdominal obesity. 
 
1.5. The time course of obesity and weight gain 
 
1.5.1. Trends and the significance of considering the time course of 
obesity 
The previous anthropometric measures explored in Sections 1.2-1.4 are all static 
measures. Recently there has been increasing interest in the effect of weight change 
on CRC risk. BMI is a static measure approximating excess general adiposity at one 
point in time. However, weight gain is a dynamic experience and eventuates over 
time rather than overnight. To date, four meta-analyses found a positive association 
between weight gain and CRC risk (46, 57-59). The continuous and cumulative 
effect of excess adiposity on CRC risk is of growing interest for three reasons.  
 
Measuring adulthood weight gain is important as it is experienced by individuals 
from most BMI categories. Malhotra et al. followed 10,038 young adults aged 
between 14 and 22 years for 18 years to understand their weight gain trajectory. Over 
this period, from early to mid-adulthood, weight gain trajectory for males and 
females in most of the BMI categories was positive and on average individuals 
experienced a weight gain of 0.5kg per year. A large proportion of males (52.3%) 
and females (34.9%) were one BMI category higher than their starting category, 
while a small proportion of males (0.5%) and females (1.9%) experienced weight 
loss and were one BMI category lower than 18 years ago (60).  
 
The advantage of using adulthood weight gain is that it is highly correlated with the 
gain of adiposity and not lean body mass. Whereas, BMI measures adiposity and lean 
body mass (6). Furthermore, weight gain during adulthood has been associated with 
weight gain in the abdominal regions, so that adult’s body shape leans towards an 
apple shape. Lara-Castro et al. followed premenopausal females with a BMI in the 
normal range for up to four years. During this time, females who experienced a 
significant weight gain, 6kg in a two-year period, experienced higher visceral 
adipose tissue accumulation relative to total body fat (61).  
 
Thirdly, carcinogenesis is a long process, and so it is important that measurements 
for adiposity do account for change over this extended period. So, being an 
anthropometric measure which incorporates time is a strength. 
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1.5.2. Adulthood weight gain and colorectal cancer incidence 
Almost all of the studies in the meta-analysis by Keum et al. and Chen et al. have 
been included in the larger two meta-analyses by Karahalios et al. and Schlesinger et 
al. (57, 59). The meta-analyses by Karahalios et al. and Schlesinger et al. 
investigated 13 and 12 studies, respectively, on the association between weight gain 
and CRC risk. All of the meta-analyses found that weight gain was associated with 
CRC or colon cancer risk. Karahalios et al. found that a 5kg increase of body weight 
was associated with 3% increased CRC risk (46). Schlesinger et al. found that 5kg 
weight gain was associated with 4% increased CRC risk and this risk remained after 
adjusting for weight at a young age. These studies found that some heterogeneity was 
explained by sex. Schlesinger found that colon cancer risk was higher in males, but 
rectal cancer risk did not differ between the sexes (58). 
 
1.6. Biological mechanism 
 
The biological mechanisms that explain the association between height, adiposity 
and CRC risk have been described comprehensively in recent articles (62-64). There 
are five systems involved in this association; growth hormones, insulin and insulin-
like growth factors, sex hormones, adipocyte-derived hormones and low-grade 
inflammation. These five systems do not act alone but rather in an interrelated and 
complex manner. It is important to note that although adult attained height is related 
to increase CRC risk, it is not the adult height that directly influences CRC risk but 
rather the genetic, environmental, hormonal and nutritional factors that affect linear 
growth and also influence CRC risk (6). 
 
 
1.6.1. Growth hormone, insulin and insulin-like growth factor 
The growth hormone and insulin growth hormone system involves growth hormone 
(GH), growth hormone receptor (GHR), growth factors (IGF-1 and IGF-2), cell 
surface receptors (IGF-1 receptor and IGF-2 receptor), binding proteins (IGF-BPs) 
and proteases.  
 
GH is secreted from the pituitary gland, and its production is regulated by two 
hypothalamic peptides called GH-releasing hormone, which induces GH production, 
and somatostatin, which inhibits GH production. GH secretion is also induced by a 
stomach peptide called ghrelin. GH can stimulate IGF-1 production, mainly from the 
liver. IGF-1, in turn, provides negative feedback by inducing the release of 
somatostatin from the hypothalamus. 
 
In the plasma, IGF is mostly present as a high molecular weight complex that 
includes IGF and a binding protein. There are six binding proteins (IGFBP 1-6) that 
bind to IGFs with high affinity. A very small proportion (less than 1%) of total IGF-1 
are in a free state in plasma. Insulin is a hormone secreted by the pancreas that 
regulates the blood glucose level. IGF-1, IGF-2, and insulin can bind with low 
affinity to each other's receptors. The exception is that free IGF-1 has high affinity 
for its receptor and the insulin receptor. The binding of insulin and free IGF-1 to a 
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receptor lead to activities that favor tumorigenesis. Free IGF-1 level have shown to 
be higher in males and this may explain the sex difference seen in the association 
between obesity and CRC risk (62).  
 
The extracellular domain of the IGF-2 receptor can break away from the cell 
membrane and circulate in the blood. As well as binding proteins, IGF-2 receptors 
are involved in reducing the bioactivity of IGF-2 to bind to the IGF-1 receptor, which 
would result in downstream carcinogenic activity.  
 
Obesity has been linked to insulin resistance, which is a state where the body does 
not respond to insulin. Subsequently, the body responds by secreting more insulin 
and this leads to hyperinsulinemia, where there is a high level of circulating insulin 
in the plasma. Hyperinsulinemia is linked to decreased insulin binding protein 1 and 
2 production in the liver. A low level of insulin binding protein 1 and 2 results in an 
increased level of free IGF-1. Studies have supported these mechanisms by showing 
that increased CRC risk is associated with high levels of serum insulin, high levels of 
IGF receptors and a low level of serum IGF binding proteins 1 and 2 (65-68).  
 
1.6.2. Sex hormones 
Obesity is linked with increased bioavailability of endogenous sex hormones (such as 
estrogen, progesterone, and androgen) through several mechanisms. Firstly, estrogen 
synthesis takes place in adipose tissue in males and postmenopausal females. 
Adipocytes produce sex hormone metabolizing enzymes such as aromatase that are 
involved in the formation of estrogen from its precursor. Secondly, (obesity 
associated) insulin and IGF-1 activity reduce the production of sex hormone binding 
globulin (SHBG) from the liver. SHBG is the main protein that binds to sex 
hormones such as testosterone and estradiol and carries it in the plasma. With 
reduced levels of SHBG, the level of bioavailable sex hormones increases.   
 
In relation to CRC risk, the use of exogenous hormones in postmenopausal females 
has been shown to lower the level of insulin and subsequently lower CRC risk (69). 
However, testosterone has an opposite effect. A study found that a low level of 
testosterone was associated with high CRC risk (68). This association may be 
mediated by the insulin pathway as a study found that androgen deprivation 
treatment is related to increased adiposity and decreased insulin sensitivity (70).  
 
1.6.3. Adipocyte-derived hormones 
Adipokines are hormones produced by adipocytes, and some examples include 
adiponectin, leptin, interleukin-6 and TNF-µ. Adiponectin is mainly produced by 
mature adipocytes commonly found in visceral adipose tissue. Unlike other 
adipokines, adiponectin has an inverse association with obesity and is linked to 
insulin sensitivity and has an anti-inflammatory role and thus is involved in anti-
tumorigenic activity. Adiponectin levels have shown to be higher in females and this 
may explain why the association between BMI and CRC risk is different for the 
sexes (62). Leptin is produced by adipocytes and is a hormone associated with 
bioactivities such as mitosis, antiapoptosis and angiogenesis and thus contributes to 
tumorigenesis. An increased level of leptin has been associated with increased BMI 
and CRC risk (71).  
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Studies have demonstrated that adipokine is linked with CRC risk (65-68). A 2014 
study by Aleksandrova et al. examined several biomarkers that may explain the link 
between adiposity and colon cancer risk. Of the eleven biomarkers studied, two 
biomarkers that explained the association between adiposity and colon cancer risk 
the most were non-high-molecular-weight (non-HMW) adiponectin and soluble 
leptin receptor (sOB-R) (72). sOB-R is a biomarker of the impaired activity of leptin, 
and this study demonstrated that it has an inverse association with colon cancer risk. 
Adiponectin is present in the plasma in different forms, including the HMW and the 
non-HMW form. This study found that non-HMW adiponectin was inversely 
associated with colon cancer risk. 
 
1.6.4. Low-grade inflammation 
In obesity, macrophage recruitment is increased in adipose tissue. This marks a 
proinflammatory state, and there is an increased influx of proinflammatory cytokines 
in adipose tissue. This can then lead to chronic inflammation which disrupts normal 
metabolic functions such as insulin resistance. HDL-C is a regulator of cellular 
apoptosis and proliferation, and a low level signals the presence of chronic 
inflammation and insulin resistance. Aleksandrova et al. found that low level of 
HDL-C was associated with increased colon cancer risk (72).  
 
1.7. The New South Wales Cancer, Lifestyle & Evaluation 
of Risk study 
This study used data from the NSW Cancer, Lifestyle & Evaluation of Risk (CLEAR) 
Study, which is funded by Cancer Council NSW. An overview of the CLEAR study 
is provided in this section, and details relevant to this current study are presented in 
the Methods chapter. 
 
Study population 
The CLEAR Study is a case-control study that began in 2006. All participants were 
NSW residents aged 18 years or older at the time of recruitment. Cases were 
recruited if they had been diagnosed with their first incident cancer (no history of 
cancer except non-melanocytic skin cancer) within 18 months before enrolment. 
Surviving spouses of cases who were free of cancer (except non-melanocytic skin 
cancer) were recruited as controls. 
 
The CLEAR Study has recruited 10,816 participants and data for 8529 participants is 
complete and ready for analysis (3,015 male cases, 3,611 female cases, 881 male 
controls and 1022 female controls). The median age of all cases and controls is 61.6 
years and 61.3 years respectively. The five cancer types with the largest number of 
cases are female breast (n=1691), prostate (n=1102), CRC (n=888), melanoma 
(n=608), and lung (n=265) (73). 
 
1.7.1. Recruitment 
A ‘targeted' and ‘non targeted' approach was adopted for recruiting cases into the 
CLEAR Study. In the CLEAR Study, 75% of the cases were recruited through the 
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‘targeted' approach. This approach involved identifying potential cases that had been 
diagnosed with any incident cancer within the last 18 months. The following 
databases were used to identify potential cases: Sydney South East Clinical Cancer 
Registry, Sydney South West Clinical Cancer Registry, Melanoma Institute of 
Australia and Hospitals Contribution Fund. The remaining participants were 
recruited through the ‘non-targeted' approach, which involved recruitment through 
community events and personal invitations by medical practitioners at select 
oncology clinic rooms. Potential cases were given a study pack that contained 
invitations for the potential case and their cancer-free spouse to participate in the 
study, an information sheet on the CLEAR Study, consent forms, and questionnaires. 
The average response rate for all cases recruited through the ‘targeted’ approach is 
25.4% while the response rate for controls is ‘estimated at 48.6%’ (73). 
 
1.7.2. Data collection 
After participants had provided consent, all were asked to complete a self-
administrated paper-based or online (since 2010) questionnaire. Once the 
participant's consent and completed questionnaire were received, an initial check for 
eligibility was conducted, and eligible participants were encouraged to provide a 
blood sample. 
 
Many of the questions in the CLEAR questionnaire originated from well-known 
studies and were modified to be suitable for a retrospective case-control, NSW study. 
In the CLEAR Study, the association between exposures of interest and cancer were 
investigated by comparing cases to sex-matched controls. 
 
All cases (recruited through the ‘targeted’ and ‘non targeted’ approach) and controls 
were asked in the CLEAR questionnaire if they had been diagnosed with any 
incident cancer within the last 18 months or if they were cancer free. Participants 
who reported having been diagnosed recently were also asked to report the cancer 
type.  Data linkage to a population-based cancer registry, the NSW Central Cancer 
Registry, was used to verify this information. As of yet, only 20% of the CLEAR 
participants have had the self-reported information verified as there are delays in the 
processing of cancer registrations at the cancer registry. All of the self-reported cases 
in the CLEAR study will be eventually verified. It was confirmed that 96% of the 
verified cases had correctly reported having cancer within the previous 18 months. 
For 9 of the 10 most common cancers in the CLEAR Study, over 94% of the verified 
cases had correctly reported their cancer type (73). 
 
1.7.3. Strengths and Limitations 
In the paper by Sitas et al., the strengths and limitations of this study are discussed in 
greater detail; however, they will be briefly summarized here (73). 
 
Cases and controls, who are spouses of cases, come from the same study base 
therefore if the controls were to be diagnosed with cancer they would have been 
recruited as a case into this study. This study design is unique and can be adapted 
where there is no population registration because the CLEAR Study has used cases 
through which to recruit controls. The CLEAR Study is resourceful because 
researchers can investigate participant's medical history because of the data linkage 
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that the study has with NSW Central Cancer Registry and will have with Medicare. 
As previously mentioned, participants are given the opportunity to provide a blood 
sample. The CLEAR Study is unique because it is the first large biobank-based 
cohort studies in Australia and is a valuable bioresource that allows future studies on 
the etiology of cancer.  
 
This study is limited by the seemingly low, case response rate. However, this is not 
surprising as cases were recruited by a once only mail invitation. There is an 
underrepresentation of the non-English speaking and indigenous population, and 
individuals diagnosed with cancer types that are rare or have poor survival. As 
controls were recruited through their partners (cases) there was concern about 
whether there was evidence for spousal concordance on obesity. Sitas et al. reports 
that there was some suggestion of spousal concordance of BMI. The sensitivity 
analysis published by Sitas et al. excluded controls that were partners of CRC cases 
in the CLEAR Study and the odds of developing CRC with increasing BMI did not 
change when these controls were excluded. This suggests that any effect of spousal 
concordance of BMI is small and if it is present, its effect on the estimate of CRC 
risk would have biased the estimate towards the null (73). Therefore, it was 
considered appropriate to include all controls whose spouses were CRC cases in this 
study. There are methodological challenges as this study has a case-control design. 
However, the CLEAR team have worked to overcome these challenges, and some of 
these methods will be discussed in Section 4.5. 
1.8. Study aims 
This thesis aims to examine the influence on colorectal cancer risk of anthropometric 
measures (height and body mass index) and changes in adiposity (regional weight 
gain and the time course of obesity and weight gain) in 856 cases and 1876 controls 
in the CLEAR study. The aims of this thesis were to examine if:  
 
1. Height increases the risk of developing colorectal cancer 
2. Body Mass Index increases the risk of developing colorectal cancer 
3. General weight gain and regional weight gain in the waist or apple region 
increases the risk of developing colorectal cancer 
4. The time course of obesity and weight gain influences colorectal cancer risk 
(i.e. longer duration of exposure to obesity or weight gain increases the risk 
of developing colorectal cancer)
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2. METHODS 
The data used in this current study comes from the CLEAR Study. An overview of 
the CLEAR Study is provided in Section 1.7. Information relevant to this current 
study is presented in this section. The questions and options in the CLEAR study that 
were used to collect data necessary for this current study are found in Section 5.2. 
 
2.1. Definition of cases and controls 
 
As described in Section 1.7.1., the majority of cases in the CLEAR Study (75%) 
were identified as recently diagnosed cancer patients through health-related 
databases and consequently recruited. These participants were classified as cases in 
the CLEAR study if they reported in the CLEAR questionnaire that they have been 
diagnosed with cancer in the preceding 18 months. For this study, only those who 
reported having been diagnosed with CRC were included as cases. Cancer-free 
spouses of cases were recruited as potential controls, and these participants were 
classified as controls in this study if they reported in the CLEAR questionnaire that 
they were cancer-free. 
 
2.2. Selection of study factors 
 
2.2.1. Height 
Participant’s self-reported current height was used to predict their CRC risk. We 
excluded participants with height less than 55 cm or greater than 270 cm as these 
were considered biologically implausible values. Height was treated as a continuous 
and a categorical variable. Separate sex-specific tertiles were created for males (less 
than 173cm (reference), 173cm to <179cm and 179cm or more) and females (less 
than 160cm (reference), 160cm to <166cm and 166cm or more). 
 
2.2.2. Body Mass Index 
Participants’ BMI was used to predict CRC risk. Participants reported their weight at 
age 20 and weight just before their (or their partner's) cancer diagnosis in kilograms 
or in stones and pounds (which was converted to kilograms by the CLEAR Study 
team). Participants reported their current height (as discussed in section 2.2.1.). 
Participant's weight and height were used to derive BMI (kg/m2) at age 20 (BMI20) 
and just before diagnosis (BMIdx).  
 
We excluded participants with weight less than 30kg or greater than 240kg and a 
BMI less than 10 kg/m2 or greater than 70 kg/m2, as these were considered 
biologically implausible values. 
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In this analysis, we treated BMI as a continuous and a categorical variable. For the 
latter, the World Health Organization’s classification were used, where BMI<18.5 
kg/m2 was defined as underweight, 18.5 kg/m2 ≤BMI<25 kg/m2 was defined as 
normal (reference), 25 kg/m2 ≤BMI<30 kg/m2 was defined as overweight, and 
BMI≥30 kg/m2 was defined as obese. For some of the analysis, the overweight and 
obese categories were combined to create the overweight/obese category. Due to the 
small sample size in the underweight category (eight males and thirty-seven females 
underweight just before diagnosis), this category was subsequently combined with 
the normal BMI category for the main analyses. 
 
2.2.3. Time course of obesity  
The purpose of this study factor was to examine how long participants had been 
affected by obesity during their adulthood and its influence on CRC risk. Responses 
to BMI at age 20 and just before diagnosis were further combined to derive the 
following groups as proxy measures for the time course of obesity in adulthood 
(BMIadult).  
 
Categories for BMIadult were based on participants who reported: 
• Having a normal BMI at age 20 and just before diagnosis (reference) 
• Being overweight/obese at age 20 and having a normal BMI just before 
diagnosis 
• Having a normal BMI at age 20 and being overweight/obese just before 
diagnosis 
• Being overweight/obese at age 20 and just before diagnosis 
• Did not respond or provided a missing/invalid response 
 
2.2.4. Proxies of obesity and the time course of weight gain 
Proxies of obesity and the time course of weight gain were created based on 
participants' responses to the following questions on weight gain, “In your 20’s and 
30’s, if you gained weight, where did you mostly put it on?” and “After age 50, if you 
gained weight, where did you mostly tend to put it on?”. The purpose of these study 
factors, the proxies of obesity and the time course of weight gain, was to examine the 
participants' experience of weight gain during early (during the 20’s and 30’s) and 
late (after the age of 50) adulthood and its influence on CRC risk. 
 
The following three sections outline how the three proxies of obesity (weight gain, 
weight gain in the waist and weight gain in the apple region) were created (Sections 
2.2.4.1. - 2.2.4.3.). 
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2.2.4.1. Weight gain 
We derived three categories for weight gain (WG) which were based on participants 
who reported: 
 
• No weight gain (reference) 
• Weight gain in any region(s) of their body 
• Did not respond or provided a missing/invalid response 
We created WG20 and WG50 using participants’ reported experience of weight gain 
in their 20’s and 30’s and after the age of 50, respectively. 
 
2.2.4.2. Weight gain in the waist 
We created four categories for regional weight gain in the waist (WGW) which were 
based on participants who reported: 
 
• No weight gain (reference) 
• Weight gain in region(s) of their body including the waist or abdomen 
• Weight gain in region(s) of their body other than the waist or abdomen  
• Did not respond or provided a missing/invalid response 
We created WGW20 and WGW50 using participants’ reported experience of regional 
weight gain in their 20’s and 30’s and after the age of 50, respectively. 
 
 
2.2.4.3. Weight gain in the apple region 
Regional weight gain was also categorized according to the American Cancer 
Society Cancer Prevention Study which defined those carrying the most weight in 
the waist and/or their upper body as apple shaped (74). 
 
We created four categories for weight gain in the apple region (WGA) which were 
based on participants who reported: 
 
• No weight gain (reference) 
• Weight gain in the apple region (i.e. weight gain in the neck, arms, chest, 
waist and or abdomen exclusively) 
• Weight gain in the non-apple region (i.e. weight gain in any region(s) of their 
body but not in the neck, arms, chest, waist and or abdomen exclusively) 
• Did not respond or provided a missing/invalid response 
WGA20 and WGA50 were created using participants’ reported experience of regional 
weight gain in their 20’s and 30’s and after the age of 50, respectively. 
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2.2.4.4. Time course of weight gain 
 
Responses to weight gain during participants' 20’s and 30’s (WG20) and after the age 
of 50 (WG50) were combined to derive the following groups as proxy measures for 
the time course of weight gain (WGadult). 
 
Categories for WGadult were based on participants who reported: 
 
• No weight gain during their 20’s and 30’s and after the age of 50 (reference) 
• Weight gain in any region(s) of their body during their 20’s and 30’s and no 
weight gain after the age of 50.  
• No weight gain during their 20’s and 30’s and weight gain in any region(s) of 
their body after the age of 50. 
• Weight gain in any region(s) of their body during their 20’s and 30’s and 
after the age of 50. 
• Did not respond or provided a missing/invalid response 
 
2.3. Covariates 
Various sociodemographic, behavioral and lifestyle covariates were examined. All of 
these covariates were treated as categorical variables.  
 
2.3.1. Sociodemographic covariates 
The sociodemographic covariates examined were age at diagnosis, ARIA plus, 
education and household income. 
 
Age 
Age at the time of the participant's (or their partner's) diagnosis was divided into 
quartiles (18-49, 50-59, 60-69 and 70 or more). All participants were 18 years old 
and above. 
 
ARIA plus 
As mentioned earlier, ARIA plus has five levels of remoteness: Major City of 
Australia, Inner Regional Australia, Outer Regional Australia, Remote Australia, and 
Very Remote Australia. The sample sizes of the latter three categories were small 
and so they were combined. 
 
Education 
Information on education was based on each participant’s highest qualification and 
was divided into six groups (no school certificate or other qualifications, school or 
intermediate certificate, Higher School or leaving certificate, trade/apprenticeship, 
certificate/diploma, university degree or higher).  
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Household income 
Information on household income was based on each participant’s usual yearly 
household income before tax, just before their (or their partner's) illness. In the 
CLEAR Study, this information is provided as eight levels of yearly household 
income (Less than $10,000, $10,000 to $24,999, $25,000 to $49,999, $50,000 to 
$74,999, $75,000 to $99,999, $100,000 to $125,000, More than $125,000 and Prefer 
not to answer). However, due to small sample sizes, the first two categories were 
combined. Similarly, the two categories ‘$100,000 to $125,000 per year’ and ‘More 
than $125,000 per year’ were combined. 
 
Country of birth 
Country of birth comprised two categories (Born in Australia and Not born in 
Australia).  
 
Family history of colorectal cancer 
Family history of CRC comprised two categories (Participant’s father and or mother 
have ever been diagnosed with CRC and Participant’s father and mother have never 
been diagnosed with CRC).  
 
2.3.2. Behavioral and lifestyle covariates 
The behavioral and lifestyle covariates examined were alcohol consumption, 
smoking status and physical activity. 
 
Alcohol consumption 
Weekly alcohol consumption just before the participant (or participant’s partner) 
became ill was divided into three categories (did not consume alcoholic drinks, 
consumed one to seven alcoholic drinks per week and consumed eight or more 
alcoholic drinks per week). The median number of alcoholic drinks consumed 
amongst participants who consumed alcoholic drinks was used as the cut-off value 
when creating the groups for analysis. 
 
Smoking status 
Smoking status comprised three categories (never, former smoker and current 
smoker). Participants in the former smoker category reported having been a regular 
smoker and ceased smoking more than five years prior to cancer diagnosis. 
Participants in the current smoker category included those who reported as still a 
regular smoker or having been a regular smoker and ceased smoking within five 
years of cancer diagnosis. This was based on the study by Stein and co-worker (75). 
 
Physical activity 
Categories for physical activity were developed as previously described in the 45 and 
Up Study (76). The intensity of the workout was considered when calculating the 
total number of physical activity sessions the participants engaged in, during a 
normal week. Vigorous exercise was given twice the weight of less vigorous exercise. 
Physical activity comprised three categories (0 to less than three, three to less than 
eight, and eight or more sessions per week).  
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Colorectal cancer screening history 
CRC screening history comprised two categories (Have ever screened for CRC and 
Never screened for CRC).  
 
2.4. Statistical analysis 
 
All analyses were performed using SAS statistical software version 9.3. A p-value 
<0.05 was considered statistically significant. A correlation coefficient of 0.6 was 
used as the cut-off value for moderate correlation. Descriptive statistics were 
presented for sociodemographic, behavioral and lifestyle characteristics of CRC 
cases and cancer-free controls. We used unconditional logistic regression to calculate 
ORs and the 95% CI for CRC risk for each of the sociodemographic, behavioral and 
lifestyle characteristics, separately for males and females. 
 
The following covariates were selected a priori: age at diagnosis, ARIA plus, 
household income, education, country of birth, family history of CRC, alcohol 
consumption, smoking status, physical activity and CRC screening history. All the 
exposure variables and covariates were treated as categorical variables. Unlike the 
other covariates, the country of birth, family history of CRC and CRC screening 
history were not included in the final model, because they did not improve the 
model’s ability to predict CRC risk as the parameter estimate did not change by 10% 
or more. 
 
We used unconditional logistic regression to calculate the ORs and the 95% CI for 
CRC for each of the exposures, BMI, the proxies of obesity (WG, WGW, and WGA) 
and the time course of obesity and weight gain, separately for males and females, 
controlling for the covariates as described above. For the exposure, BMI at age 20, 
we controlled for BMI just before diagnosis in addition to the covariates described 
above. A sensitivity analysis was carried out, where those who were underweight 
were excluded. We examined the correlation between categorical variables using 
polychoric correlation.  
 
Missing data for the covariates and some of the exposure variables (height, BMI20 
and BMIdx) were excluded from the analysis while missing data for the proxies of 
obesity were placed in a separate category for analysis. 
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3. RESULTS 
3.1. Description of the study population 
 
3.1.1. Characteristics of the study population 
Table 1 shows the crude odds ratios (ORs) for CRC risk in relation to the covariates, 
separately for males and females. There were 2,728 participants in this study (483 
male CRC cases, 373 female CRC cases, 907 male controls and 965 female controls).  
In both sexes, CRC risk appeared to be directly related to age, and be inversely 
related to ARIA plus, education and household income. CRC risk was directly 
related to smoking status in both males and females, and it was inversely related to 
alcohol consumption and physical activity in females, but not related in males. 
 
3.1.2. Missing data 
Those with missing information at baseline for ARIA plus (n=16), education (n=54), 
household income (n=78), alcohol consumption (n=35), smoking status (n=59) or 
physical activity (n=17) were excluded. Participants with an extreme or missing BMI 
at age 20 (male: n=141; female: n=150) or just before diagnosis (male: n=80; female: 
n=118) were excluded. Subjects with missing responses for WG20 (male: n=42; 
female: n=37) or WG50 (male: n=290; female: n=248) were placed in separate 
categories.  
 
Male cases with a missing response for WG50 correlated with being normal or 
overweight just before diagnosis (p=0.03, data shown in Section 5.3.3.). Male 
controls with a missing response for WG50 correlated with being overweight or obese 
at the age of 20 (p=0.007, data shown in Section 5.3.3.). Female cases with a missing 
response for WG50 correlated with being obese at the age of 20 (p=0.04, data shown 
in Section 5.3.3.). Female controls with a missing response for WG50 correlated with 
having a normal BMI just before diagnosis (p=0.0003, data shown in Section 5.3.3.). 
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Table 1 Characteristics of covariates of colorectal cancer risk for cases and controls in this analysis 
Characteristics 
Male   Female 
Cases, n %* Controls, n % Crude OR   Cases, n % Controls, n % Crude OR  
N=483 100.0 N=907 100.0 (95%CI)   N=373 100.0 N=965 100.0 (95%CI) 
Median age (years) 64  56-71 59 51-67    63 53-71 61 53-67   
Age categories (years)                 
18 to 49 51 10.6 201 22.2 1.00  65 17.4 165 17.1 1.00 
50 to 59 114 23.6 257 28.3 1.75 (1.20-2.55)  83 22.3 258 26.7 0.82 (0.56-1.19) 
60 to 69 179 37.1 282 31.1 2.50 (1.75-3.59)  114 30.6 387 40.1 0.75 (0.52-1.07) 
70 and older 139 28.8 167 18.4 3.28 (2.24-4.80)  111 29.8 155 16.1 1.82 (1.25-2.65) 
p-value       <0.0001        <0.0001 
ARIA plus categories                  
Major Cities of Australia 307 63.6 517 57.0 1.00  240 64.3 528 54.7 1.00 
Inner Regional Australia 124 25.7 280 30.9 0.75 (0.58-0.96)  92 24.7 268 27.8 0.76 (0.57-1.00) 
Rural Australia a 52 10.8 110 12.1 0.80 (0.56-1.14)  41 11.0 169 17.5 0.53 (0.37-0.78) 
p-value       0.06        0.002 
Education categories                 
No school certificate or other qualifications 57 11.8 71 7.8 1.00  42 11.3 77 8.0 1.00 
School or intermediate certificate 78 16.1 114 12.6 0.85 (0.54-1.34)  100 26.8 273 28.3 0.67 (0.43-1.04) 
Higher school or leaving certificate 49 10.1 82 9.0 0.74 (0.45-1.22)  39 10.5 89 9.2 0.80 (0.47-1.37) 
Trade/apprenticeship 82 17.0 134 14.8 0.76 (0.49-1.19)  19 5.1 42 4.4 0.83 (0.43-1.60) 
Certificate/diploma 100 20.7 182 20.1 0.68 (0.45-1.05)  72 19.3 231 23.9 0.57 (0.36-0.91) 
University degree or higher 117 24.2 324 35.7 0.45 (0.30-0.68)  101 27.1 253 26.2 0.73 (0.47-1.14) 
p-value       0.0003        0.2 
Household Income categories                 
Less than $25,000 121 25.1 115 12.7 1.00  108 29.0 184 19.1 1.00 
$25,000 to $49,999 99 20.5 180 19.8 0.52 (0.37-0.75)  69 18.5 208 21.6 0.57 (0.39-0.81) 
$50,000 to $74,999 66 13.7 135 14.9 0.47 (0.32-0.69)  47 12.6 140 14.5 0.57 (0.38-0.86) 
$75,000 to $100,000 48 9.9 115 12.7 0.40 (0.26-0.61)  32 8.6 108 11.2 0.51 (0.32-0.80) 
More than $100,000 94 19.5 269 29.7 0.33 (0.24-0.47)  54 14.5 183 19.0 0.50 (0.34-0.74) 
Prefer not to answer 55 11.4 93 10.3 0.56 (0.37-0.86)  63 16.9 142 14.7 0.76 (0.52-1.11) 
p-value         <0.0001           0.002 
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Table 1 (continued) 
Characteristics Male   Female 
Cases, n % Controls, n % Crude OR   Cases, n % Controls, n % Crude OR  
N=483 100.0 N=907 100.0 (95%CI)   N=373 100.0 N=965 100.0 (95%CI) 
Alcohol consumption categories 
(drinks per week) 
                
0 104 21.5 182 20.1 1.00  165 44.2 352 36.5 1.00 
1 to 7 143 29.6 317 35.0 0.79 (0.58-1.08)  119 31.9 378 39.2 0.67 (0.51-0.89) 
 8 or more 236 48.9 408 45.0 1.01 (0.76-1.35)  89 23.9 235 24.4 0.81 (0.60-1.10) 
p-value       0.1        0.02 
Smoking status categories                 
Never 204 42.2 494 54.5 1.00  209 56.0 653 67.7 1.00 
Former 194 40.2 303 33.4 1.55 (1.22-1.98)  109 29.2 207 21.5 1.65 (1.24-2.18) 
Current 85 17.6 110 12.1 1.87 (1.35-2.60)  55 14.7 105 10.9 1.64 (1.14-2.35) 
p-value       <0.0001        0.0004 
Physical activity categories (sessions 
per week) 
                
0 to <3 109 22.6 188 20.7 1.00  116 31.1 219 22.7 1.00 
3 to <8 181 37.5 370 40.8 0.84 (0.63-1.13)  155 41.6 443 45.9 0.66 (0.49-0.88) 
8 or more 193 40.0 349 38.5 0.95 (0.71-1.28)  102 27.3 303 31.4 0.64 (0.46-0.87) 
p-value         0.5           0.007 
a includes participants classified in Outer Regional Australia, Remote Australia, and Very Remote Australia  
*In this percentage column and the other percentage columns that follow, the interquartile ranges for age are provided  
All p-values test for equal proportions in each category of the covariate 
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3.2. Study factors and Colorectal Cancer 
Table 2 shows the adjusted odds ratios for CRC risk in relation to the study factors, 
separately for males and females.  
 
CRC risk appeared not to be related to height in males and females. 
 
In males, CRC risk was directly related to BMI just before diagnosis but was not 
related to BMI at age 20. In males, CRC risk was also directly related to BMI at age 
20 when BMI just before diagnosis was not adjusted for (data not shown). When 
BMI just before diagnosis was accounted for, CRC risk was not related to BMI at 
age 20 in males.  In females, CRC risk was not related to BMI at age 20 and just 
before diagnosis. CRC risk did not change when participants classified as 
underweight were excluded from the analysis (data not shown).  
 
In males, CRC risk appeared to be increased for those who had a normal BMI at age 
20 and were overweight just before diagnosis compared to those who had a normal 
BMI at both time points. CRC risk appeared to be even greater for those who were 
overweight at both time points. In females, CRC risk appeared not to be related to 
the time course of obesity.  
 
In both sexes, CRC risk was not related to the proxies of obesity (WG, WGW, and 
WGA) during participant’s 20’s and 30’s and after the age of 50. In addition, CRC 
risk was not related to the time course of weight gain. 
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Table 2 Odds ratios (ORs) for CRC risk in relation to the study factors, separately for males and females 
Characteristics Male   Female 
Cases, n %* Controls, n % Adjusted ORa  Cases, n % Controls, n % Adjusted ORa 
N=483 100.0 N=907 100.0 (95% CI)   N=373 100.0 N=965 100.0 (95% CI) 
Median height (cm) 176 172-180  178 172-182    163 157-168 163 157-168   
Height categoriesb                
Tertile 1 (shortest) 131 27.1 229 25.2 1.00  122 32.7 299 31.0 1.00 
Tertile 2 252 52.2 439 48.4 1.14 (0.86-1.50)  146 39.1 382 39.6 0.98 (0.73-1.33) 
Tertile 3 (tallest) 100 20.7 239 26.4 1.00 (0.72-1.41)  105 28.2 284 29.4 0.99 (0.71-1.37) 
p-value         0.6           1.0 
Median BMI at age 20 (kg/m2) 23.7 21.6-25.6  23.2 21.6-25.1    21.0 19.6-23.1 21.1  19.4-23.1  
BMI at age 20 categories (kg/m2)c                 
10 to <25 (normal) 329 68.1 663 73.1 1.00  329 88.2 836 86.6 1.00 
25 to 70 (overweight/obese)d 154 31.9 244 26.9 1.06 (0.79-1.42)  44 11.8 129 13.4 0.83 (0.55-1.26) 
25 to <30 (overweight) 127 26.3 207 22.8 1.05 (0.78-1.42)  37 9.9 101 10.5 0.94 (0.60-1.46) 
30 to 70 (obese) 27 5.6 37 4.1 1.12 (0.62-2.00)  7 1.9 28 2.9 0.50 (0.21-1.20) 
p-valuee       0.7        0.4 
Median BMI just before diagnosis (kg/m2) 27.5  25.1-30.9 26.6 24.5-29.4    25.8 23.3-29.6 25.5  23.1-29.4  
BMI just before diagnosis categories (kg/m2)f                 
10 to <25 (normal) 116 24.0 282 31.1 1.00  163 43.7 437 45.3 1.00 
25 to 70 (overweight/obese)d 367 76.0 625 68.9 1.48 (1.13-1.93)  210 56.3 528 54.7 1.07 (0.83-1.38) 
25 to <30 (overweight) 217 44.9 430 47.4 1.28 (0.96-1.70)  123 33.0 313 32.4 1.06 (0.80-1.42) 
30 to 70 (obese) 150 31.1 195 21.5 2.01 (1.44-2.80)  87 23.3 215 22.3 1.08 (0.77-1.50) 
p-valuee         0.004           0.6 
Time course of obesity                 
BMI at age 20 BMI just before diagnosis                 
Normal Normal 108 22.4 271 29.9 1.00  157 42.1 425 44.0 1.00 
Overweight Normal 8 1.7 11 1.2 1.27 (0.47-3.42)  6 1.6 12 1.2 1.23 (0.44-3.44) 
Normal Overweight 221 45.8 392 43.2 1.39 (1.04-1.87)  172 46.1 411 42.6 1.13 (0.86-1.48) 
Overweight Overweight 146 30.2 233 25.7 1.69 (1.22-2.34)  38 10.2 117 12.1 0.90 (0.59-1.39) 
p-value          0.02           0.7 
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Table 2 (continued) 
Characteristics Male   Female 
Cases, n % Controls, n % Adjusted ORa  Cases, n % Controls, n % Adjusted ORa 
N=483 100.0 N=907 100.0 (95% CI)   N=373 100.0 N=965 100.0 (95% CI) 
Weight gain during 20's and 30's        		 	   		 		 	
No weight gain 89 18.4 168 18.5 1.00  61 16.4 142 14.7 1.00 
Weight gain in any region 378 78.3 713 78.6 1.18 (0.87-1.60)  302 81.0 796 82.5 0.88 (0.62-1.24) 
Invalid/missing 16 3.3 26 2.9 	  10 2.7 27 2.8  
p-value       0.3	 	   	 	 0.5 
Weight gain after age 50       	    		 		  
No weight gain 51 10.6 80 8.8 1.00	 	 26 7.0 63	 6.5	 1.00	
Weight gain in any region 364 75.4 605 66.7 0.93 (0.62-1.38)  275 73.7 726 75.2 1.00 (0.59-1.67) 
Invalid/missing 68 14.1 222 24.5 	  72 19.3 176 18.2  
p-value       0.7      	 	 1.0 
Weight gain in waist during 20's and 30's       		 	      
No weight gain 89 18.4 168 18.5 1.00  61 16.4 142 14.7 1.00 
Weight gain not in waist/abdomen 33 6.8 48 5.3 1.45 (0.84-2.49)  77 20.6 229 23.7 0.78 (0.51-1.18) 
Weight gain in waist/abdomen 345 71.4 665 73.3 1.16 (0.85-1.57)  225 60.3 567 58.8 0.92 (0.64-1.31) 
Invalid/missing 16 3.3 26 2.9 	  10 2.7 27 2.8  
p-value       0.4    	 	 0.5 
Weight gain in waist after age 50              
No weight gain 51 10.6 80 8.8 1.00  26 7.0 63 6.5 1.00 
Weight gain not in waist/abdomen 14 2.9 9 1.0 2.07 (0.80-5.36)  36 9.7 97 10.1 0.94 (0.50-1.77) 
Weight gain in waist/abdomen 350 72.5 596 65.7 0.91 (0.61-1.35)  239 64.1 629 65.2 1.01 (0.60-1.70) 
Invalid/missing 68 14.1 222 24.5   72 19.3 176 18.2  
p-value     0.2       0.9 
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Table 2 (continued) 
Characteristics Male   Female 
Cases, n % Controls, n % Adjusted ORa  Cases, n % Controls, n % Adjusted ORa 
N=483 100.0 N=907 100.0 (95% CI)   N=373 100.0 N=965 100.0 (95% CI) 
Weight gain in apple region during 20's and 
30's 
      		 	   		 		 	
No weight gain 89 18.4 168 18.5 1.00  61 16.4 142 14.7 1.00 
Weight gain not in non-apple region 101 20.9 160 17.6 1.44 (0.98-2.10)  198 53.1 540 56.0 0.88 (0.61-1.26) 
Weight gain in apple region 277 57.3 553 61.0 1.11 (0.81-1.51)  104 27.9 256 26.5 0.88 (0.59-1.30) 
Invalid/missing 16 3.3 26 2.9 		 	 10 2.7 27 2.8  
p-value       0.1    		 		 0.8 
Weight gain in apple region after age 50       		 	   		 		 	
No weight gain 51 10.6 80 8.8 1.00  26 7.0 63 6.5 1.00 
Weight gain not in non-apple region 62 12.8 76 8.4 1.18 (0.71-1.96)  164 44.0 450 46.6 0.96 (0.57-1.63) 
Weight gain in apple region 302 62.5 529 58.3 0.89 (0.60-1.32)  111 29.8 276 28.6 1.06 (0.61-1.83) 
Invalid/missing 68 14.1 222 24.5 		 	 72 19.3 176 18.2  
p-value       0.3        0.8 
Time course of weight gain                 
Weight gain in the 
20's and 30's 
Weight gain after age 
50 
                
No No 17 3.5 31 3.4 1.00  9 2.4 18 1.9 1.00 
Yes No 31 6.4 46 5.1 1.21 (0.55-2.64)  15 4.0 44 4.6 0.71 (0.25-2.03) 
No Yes 66 13.7 121 13.3 0.95 (0.48-1.91)  47 12.6 106 11.0 1.03 (0.41-2.62) 
Yes Yes 290 60.0 469 51.7 1.13 (0.59-2.14)  224 60.1 599 62.1 0.84 (0.35-2.02) 
Invalid/missing  79 16.4 240 26.5    78 20.9 198 20.5  
p-value           0.8 		         0.7 
a adjusted for Age, ARIA plus, Household income, Education, Smoking status, Alcohol consumption and Physical activity (BMI just before diagnosis was further adjusted for BMI at age 20) 
b When height was treated as a continuous variable, height was unrelated to CRC risk (OR:1.00, 95% CI:0.98-1.01 for males and OR:1.00, 95%CI:0.98-1.02 for females) 
c When BMI at age 20 was treated as a continuous variable, BMI at age 20 was unrelated to CRC risk (OR:1.00, 95%CI:0.96-1.04 for males and OR:0.99, 95% CI:0.95-1.03 for females) 
d The overweight and obese categories were combined to create one category (overweight/obese) 
e P-value tests for equal proportions in the overweight/obese and the normal (reference) categories 
f When BMI just before diagnosis was treated as a continuous variable, BMI just before diagnosis was directly related to CRC risk in males but not in females (OR:1.05, 95%CI:1.03-1.08 for males 
and OR:1.01, 95%CI:0.99-1.03 for females) 
*In this percentage column and the other percentage columns that follow, the interquartile ranges for each value of height and BMI (at age 20 and just before diagnosis) are provided 
Height tertiles were sex-specific: males (Less than 173 cm, 173 cm to <181 cm, 181 cm or more) and females (Less than <160 cm, 160 cm to <168 cm, 168 cm or more) 
P-values test for equal proportions in each category of a covariate 
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4. DISCUSSION 
This study found that, in males but not in females, being overweight or obese just 
before diagnosis was directly related to CRC risk and being overweight or obese at 
the age of 20 and just before diagnosis was directly related to an even greater CRC 
risk. However, the proxies of obesity (WG, WGW, and WGA) did not predict 
participant’s CRC risk. In males, WGW was not a discriminative anthropometric 
measure during their 20’s and 30’s or after the age of 50 because most males (cases 
and controls) gained weight in the waist rather than elsewhere. 
 
4.1. Height and colorectal cancer 
A 2007 publication by WCRF concluded that there is convincing evidence that adult 
attained height is associated with increased risk of CRC and the CLEAR Study was 
used to validate this statement. In this study, CRC risk appeared to be unrelated to 
adult attained height. Many cohort and nested case-control studies found that height 
was directly related to an increased CRC risk of between 6% to 38% (77-83). 
However, like our study, other cohort and co-twin control studies found that height 
appeared unrelated to CRC risk (84-87). Studies have suggested that the association 
between height and CRC risk may be different for specific sites of the colon and 
rectum. A cohort study by Shin et al. found that height was associated with rectal 
cancer and distal colon cancer but not with proximal colon cancer (88). However, a 
cohort study by Pischon et al. found that height was associated with colon cancer risk 
but not with rectal cancer risk (52). These inconsistencies suggest that the association 
between height and CRC risk and in particular the site-specific associations need 
further investigation and may explain our null findings.  
 
4.2. Body Mass Index and colorectal cancer 
WCRF stated that there is convincing evidence that greater body fatness is a cause of 
CRC and the CLEAR Study was again used to validate this statement. In this study, 
BMI just before diagnosis appeared to be directly related to CRC risk in males but 
not in females. Similarly, other cohort studies found that the association between 
BMI and CRC risk was only observed in males (89, 90) and the Million Women 
Study found that CRC risk was not related to BMI in females (91). Also, meta-
analyses have found that the associations between BMI and CRC risk or colon cancer 
risk was stronger in males compared to females or was only seen in males (43, 48, 
92). However, the cohort study by Odegaard et al. found that CRC risk was directly 
related to BMI in both males and females (93). An explanation for the disagreement 
between our finding and the findings of Odegaard et al. may be that they did not use 
the World Health Organization’s BMI categories because all of their participants 
were from Japan and they wanted to examine CRC risk for the underweight category. 
Also, two cohort studies (by Poynter et al. and Kabat et al.) found that BMI was 
associated with CRC risk in females (94, 95). All participants in these two studies 
were postmenopausal women, and this may explain the lack of an association 
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between CRC risk and BMI seen in our female participants (some of whom were not 
postmenopausal).  
 
 
In this study, BMI at age 20 appeared not to be related to CRC risk. Similarly, the 
cohort studies by Han et al. and Li et al. (considered in Section 5.1.2.) did not find an 
association between BMI during early adulthood and CRC risk (89, 96). However, 
the remaining studies in Section 5.1.2. found an association. An explanation for this 
disagreement may be that most of the studies did not explore the association between 
BMI during early adulthood and CRC risk, independent of BMI during late 
adulthood, by adjusting for the latter BMI. Of all the studies in Section 5.1.2., only 
two cohort studies (by Zhang et al. and Han et al.) explored the independent risk of 
BMI during early adulthood (96, 97). In this study, 43.8% of the participants had a 
normal BMI at age 20 and were overweight or obese just before diagnosis. Therefore, 
as described in the methods chapter, it seemed appropriate to adjust for BMI just 
before diagnosis when determining the association between BMI at age 20 and CRC 
risk. This is because some of the participants in the reference category, those with a 
normal BMI at age 20, may have become overweight or obese just before diagnosis 
and have become exposed to obesity later in their adulthood. 
 
4.3. The time course of obesity and colorectal cancer 
In males but not females, having a normal BMI at age 20 and being overweight or 
obese just before diagnosis was linked to a 39% increased CRC risk, compared to 
participants who had a normal BMI at both time points. The CRC risk increased 
further (69%) for males who were overweight or obese at both time points.  
 
Although studies have investigated the cumulative effect of weight gain on cancer 
risk, studies on the cumulative effect of being overweight during life and cancer risk 
are scarce. A 2016 cohort study by Arnold et al. was the first study to investigate the 
effect of overweight duration and cancer risk in an older population (98). Like our 
study, this study found that indeed longer overweight duration was significantly 
associated with increased CRC risk and this risk was higher for males compared to 
females. A 2011 case-control study by Lu et al. used a similar approach to 
investigate the cumulative effect of obesity as our study (99). Long-term obesity was 
defined as being overweight during participant’s 20’s and 30’s and being overweight 
thereafter. In females, they found long-term obesity was associated with greater risk 
of endometrial cancer compared to females who had a normal BMI throughout 
adulthood.  
 
4.4. Proxies of obesity and colorectal cancer 
Although we hypothesized that the experience of weight gain, weight gain in the 
waist and weight gain in the apple region would be positively associated with CRC 
risk, this study demonstrated that they did not predict CRC in either sex. 
 
Most of our participants experienced weight gain during their 20’s and 30’s and after 
the age of 50. This is noteworthy for two reasons. Firstly, several studies also found 
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that most of their participants experienced weight gain or found that their BMI 
increased from early adulthood (99-101). Secondly, this finding may explain the high 
prevalence of obesity in Australian adults (as discussed in Section 1.3.1). 
 
A cohort study by Renehan et al. found that weight gain from the age of 18 years to 
35 years was associated with colon and rectal cancer risk in males and the 
association was stronger compared to females (102). Similarly, in our study, in males 
but not in females, weight gain during their 20’s and 30’s was associated with an 
increased CRC risk compared to those who did not experience weight gain, although 
the relevant confidence interval crossed one and so the significance of the result is 
not clear. This finding may be important because a large proportion of males 
experienced weight gain during their 20’s and 30’s. Together our findings and the 
findings of Renehan et al. suggest that weight gain during early adulthood should be 
avoided as it is positively associated with CRC risk. 
 
Finally, in males but not in females, weight gain in the waist during their 20’s and 
30’s had an increased (but not statistically significant) CRC risk compared to those 
who did not experience weight gain. Like the finding discussed above, this result is 
potentially important because a large proportion of males experienced weight gain in 
the waist during their 20’s and 30’s. Similar to our finding, a cohort study by Song et 
al. found that males who experienced an increase of ten centimeters or more in their 
waist circumference had a 59% increased CRC risk compared to males who 
maintained their waist circumference during a nine-year period. This association was 
maintained even after adjusting for weight change. When these findings are 
considered together, it suggests that the redistribution of fat centrally during 
adulthood may be linked with increased risk of CRC in males only (103). 
 
4.5. Strengths and limitations of the study 
This study had a large sample size where measures of obesity were collected at 
various time points. The measures included BMI, the commonly used measure of 
adiposity, and more novel approaches to the measurement of weight gain like the 
time course of obesity and weight gain, and three proxy measures of obesity. The 
advantage of these proxies of obesity over other measures is that they require no 
specific measurements. Many studies have investigated the association between 
weight change and cancer risk, where weight or BMI change are used to measure the 
cumulative effect of obesity. A 2015 meta-analysis by Karahalios et al., using data 
from 14 studies published between 1997 to 2014, found that a 5 kilogram weight 
gain was associated with a 3% increased risk of developing CRC (46). However, to 
our knowledge, this study is one of the first to combine BMI in early and late 
adulthood to create a single measure of the cumulative effect of obesity throughout 
adulthood and investigate its association with CRC risk.  
 
Data used in this current study comes from the CLEAR Study, and there are several 
advantages of using the CLEAR Study. Firstly, it is an NSW population study, 
therefore, the conclusions from this study will be relevant locally. Secondly, it is 
important to use Australian data to answer questions relevant to Australian needs, 
such as the high prevalence of CRC and obesity, and their association. Finally, being 
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an in-house dataset meant that this large epidemiology bioresource was easily 
accessible. 
 
The analysis adjusted for many behavioral and lifestyle factors that have been shown 
to be associated with CRC, such as smoking, alcohol and physical activity (104). 
However, other risk factors, such as participants' history of hormone replacement 
therapy use, were not included (104, 105). Studies have shown that the use of 
postmenopausal hormone therapy is linked with lowering CRC risk in females (106). 
Although information on participants' hormone replacement therapy use was 
collected in the CLEAR Study, appropriately analyzing this information is complex 
and was considered beyond the scope of this study. The relationship between CRC 
risk and height or the proxies of obesity were the same for males and females, 
suggesting (although not guaranteeing) that hormone replacement therapy use may 
not have altered some of the findings for females. Of course, this information on 
postmenopausal hormone therapy is not relevant to the analyses for males.  
 
Information on participants’ dietary intake was collected in the CLEAR study and 
consumption of red meat, and low fruit and vegetable consumption has been shown 
to be linked with increased CRC risk (see Section 1.1.3.9.). However, this 
information was also not accounted for as literature suggests that self-reported 
dietary intake is affected by information bias. Hebert describes that information 
collected after a diagnosis of a disease of interest in a case-control study can be 
biased if cases are asked to recall diet-related information from their past, or it may 
be biased as their diet may have been modified since their diagnosis (107). The 
association between height or obesity and CRC risk may have altered if dietary 
intake was accounted for in this study. 
 
There are inherent limitations in using a case-control design, such as selection bias, 
recall bias, and reverse causation. Although no groups were excluded from 
recruitment, the participants in the CLEAR Study were found to under-represent 
some groups, such as people of non-English speaking background, and Aboriginal 
and Torres Strait Islander people. This may limit the generalizability of the result, 
and if this study is expanded, targeted recruitment of those underrepresented maybe 
beneficial (73). As mentioned in Section 1.7.1., the CLEAR study used a ‘targeted’ 
and a ‘non-targeted’ approach to recruit cases. Using two approaches to recruit cases 
would not have affected the association between height or obesity and CRC risk as 
height or obesity would not be associated with the recruitment method. It is possible 
that the ‘targeted’ and the ‘non-targeted’ approaches may have recruited cases with 
different socioeconomic characteristics. But, as this study adjusted for 
socioeconomic factors, like education and income, the two different recruitment 
approaches should not have affected the conclusions of this study. Due to the 
retrospective nature of this study design, questions shown to be robust in cohort and 
case-control designs and that require modest recall were included in the CLEAR 
questionnaire (73). Park et al. found that male and female participants over-reported 
their height and under-reported weight, waist circumference and hip circumference. 
This bias affected participants with a higher BMI to a greater extent. Although these 
anthropometric measures are all affected by recall bias, Park et al. found that BMI 
may be less affected as weight and height were more accurately reported compared 
to waist circumference and hip circumference (44). It is possible that BMI just before 
diagnosis may have been affected by reverse causality as cases may have 
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experienced weight loss secondary to their CRC diagnosis. If this was the case, the 
estimate of the effect of obesity on CRC risk would have biased towards the null. 
The proportion of subjects with missing or invalid information on weight gain after 
the age of 50 was high (Table 2). So, some of the participants did not report their 
weight gain experience after the age of 50, which for most requires recollection of a 
recent experience. The reason for this is unclear, but it may be that as weight gain is 
a common experience (as discussed in Section 4.4.), participants with missing or 
invalid information may not have been able to clearly remember the timing of their 
weight gain (i.e. whether it was just before or after the age of 50). 
 
Male cases who had a missing or invalid response to weight gain after the age of 50 
had a lower BMI just before diagnosis, and male controls had a higher BMI at the 
age of 20, compared to those who responded (Table 9). Since these subjects could 
not be included in the analysis, this could have resulted in selection bias, as cases and 
controls were affected differently, and the effect would have been to bias the findings 
on the association between the proxies of obesity and CRC risk upwards. Female 
cases who had a missing or invalid response to weight gain after the age of 50 had a 
higher BMI at the age of 20, and female controls had a lower BMI just before 
diagnosis, compared to respondents (Table 10). This also could have resulted in 
selection bias and biased the findings downwards. 
 
There was insufficient sample size to investigate the association between the 
anthropometric measures and CRC risk for the different anatomical sub-sites of CRC. 
Studies suggest that the association between height and CRC risk may be different 
for the subsites (52, 88). Similarly, several studies have shown that BMI was 
associated with colon cancer risk but could not predict rectal cancer (51, 52, 93, 102, 
108). Therefore, this suggests that the association found in this study between BMI 
and CRC may be attenuated by the inclusion of rectal cancer, since rectal cancer does 
not appear to be related to BMI. 
 
4.6. Recommendation for future action 
In our study, we found using BMI measured at one point in time to determine an 
individual's CRC risk may provide a limited understanding of the relationship 
between adiposity and CRC risk. When using BMI at one point in time, male 
participants who were overweight or obese just before diagnosis had an increased 
CRC risk (48%) compared to male participants with a normal BMI. However, these 
participants could have been overweight or obese at the age of 20 as well, and their 
CRC risk would have been greater (69% increased CRC risk). This finding suggests 
that monitoring BMI over time provides a better assessment of CRC risk related to 
adiposity than is obtained when using BMI measured at one point in time. 
 
The sample size for the group of males who were overweight or obese at age 20 and 
had normal BMI just before diagnosis was very small (1.7% of male cases and 1.2% 
of males controls). This finding suggests that it is unlikely for male participants who 
were overweight or obese at age 20 to experience weight loss and have a normal 
BMI just before diagnosis. However, our findings suggest that prolonged weight gain 
results in additional CRC risk over and above that arising from being overweight at a 
single time point.  Therefore, male participants who are overweight or obese at age 
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20 should be strongly advised to maintain a healthy weight throughout adulthood to 
avoid the associated high risk of developing CRC. Taghizadeh et al. found that 
chronic obesity was positively linked with cancer mortality in females. The findings 
from Taghizadeh et al. study and our study serves as a reminder that avoiding 
chronic obesity may result in lowering CRC risk and cancer mortality (109), in 
addition to other health gains that may result.  
 
4.7. Synthesis/summary 
This study demonstrated that BMI just before diagnosis is a CRC risk predictor in 
males only. Health professionals should particularly encourage males to maintain a 
healthy weight, and for those who are overweight or obese at age 20 to monitor their 
weight throughout adulthood, and lose weight if they can, as early and persistent 
exposure to obesity places males at considerable risk of developing CRC. The 
proxies of obesity did not predict CRC risk in this study. In the clinical and research 
setting, BMI should still be used in relation to CRC risk, despite its flaws, as it 
appears to be a better CRC predictor than the available proxies of obesity.  
 
 
49 
5. APPENDIX 
5.1. Summary of relevant individual studies 
 
5.1.1. Adult height and colorectal cancer incidence 
The individual studies that explored the association between adult height and the risk 
of developing colon cancer, rectal cancer or CRC were reviewed and summarized in 
this section. 
 
Pubmed was used to search for studies on the link between height and CRC risk. 
Search for literature was conducted in 2014 and updated in 2016. It included the 
following search string: (colon or rectal or colorectal) and cancer and (risk or 
incidence) and (height or stature). Through Pubmed, 367 papers were found, and 27 
papers met the inclusion criteria. The search strategy is detailed in Figure 9. These 
papers were published between 1988 and 2014. 
 
Table 3 summarizes 15 of the most recent studies on the association between height 
and CRC incidence. These papers were published between 2005 and 2014 and 
examined the association in various countries within Europe, North America, and 
Asia. The sample size of databases that these papers used to examine the association 
between height and CRC incidence varied from 20,000 to two million. 
 
Figure 9 Flowchart of the search strategy for studies on the association between 
height and colorectal cancer risk 
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Table 3 Summary of the individual studies that explored the association between height and colorectal cancer incidence 
Author, 
Year 
Journal Country Database Study type Study period 
(recruitment 
to follow-up) 
Sample size 
(after 
exclusions) 
Colorectal 
cancer 
cases 
Exposure/ 
Outcome 
Relative risk (95% CI) Confounders adjusted 
for 
Males Females  
Wiren et 
al., 2014 
(81) 
Cancer 
Causes 
and 
Control 
Austria, 
Norway, 
Sweden 
Metabolic 
Syndrome and 
Cancer 
Project 
Prospective 
cohort 
1974-2006 585,928 4,720 Height (per 5cm 
increase) 
    date of birth, age at health 
examination  
colon cancer 1.09 (1.05-1.13) 1.11 (1.06-1.16) 
rectal/anal cancer 1.06 (1.01-1.11) 1.09 (1.02-1.17) 
Kabat et 
al., 2014 
(110) 
Cancer 
Causes 
and 
Control 
USA National 
Institute of 
Health-AARP 
Diet and 
Health Study  
Prospective 
cohort 
1995-2006 481,197 6,189 Height (per 10cm 
increase) 
   age at entry, education, race, 
smoking status, BMI, 
alcohol intake, physical 
activity, family history, and 
colonoscopy screening, age 
at first menstruation (in 
females only) 
colon cancer 1.10 (1.05-1.16) 1.19 (1.10-1.29) 
rectal cancer 1.09 (1.02-1.17) 1.12 (0.99-1.26) 
Boursi 
et al., 
2014 
(82) 
European 
Journal of 
Gastroent
erology & 
hepatolog-
y 
 
UK The Health 
Improvement 
Network 
Nested case-
control 
 1995-2013 36,825  9,978 Height (per 10cm 
increase) 
    diabetes mellitus, ischemic 
heart disease, connective 
tissue diseases, BMI, 
smoking history alcohol 
consumption, chronic use of 
Aspirin/NSAIDs, and 
performance of screening 
colonoscopy  
colorectal cancer 1.10 (1.05-1.15) 1.16 (1.10-1.23) 
Kabat et 
al., 2013 
(77) 
Internati-
onal 
Journal of 
Cancer 
Canada Canadian 
National 
Breast 
Screening 
Study 
Prospective 
cohort 
1980-2000 88,256 1,096 Height (per 10cm 
increase) 
  age at entry, menopausal 
status, years of education, 
pack-years of smoking, oral 
contraceptive use, hormone 
therapy 
colorectal cancer  1.12 (1.01-1.23) 
colon cancer  1.11 (0.99-1.25) 
rectal cancer   1.14 (0.96-1.35) 
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Table 3 (continued) 
Author, 
Year 
Journal Country Database Study type Study period 
(recruitment 
to follow-up) 
Sample size 
(after 
exclusions) 
Colorectal 
cancer 
cases 
Exposure/ 
Outcome 
Relative risk (95% CI) Confounders adjusted 
for Males Females 
Kabat et 
al., 2013 
(78) 
Cancer 
Epidemiol-
ogy, Biom-
arkers 
&Prevent-
ion 
USA Women's 
Health 
Initiative 
Prospective 
cohort 
1993-2005 144,701 1,904 Height (per 10 cm 
increase) 
    age, servings of alcohol per 
week, pack-years of 
smoking, hormone therapy, 
family history of CRC, 
physical activity, red meat 
intake, folate intake, aspirin 
use, diabetes, education, 
ethnicity, randomization 
status in each of the clinical 
trials, age at menarche for 
CRC only) 
colorectal cancer   1.15 (1.07-1.24) 
colon cancer   1.14 (1.04-1.24) 
rectal cancer   1.26 (1.03-1.55) 
Park et al., 
2012 
(44) 
Internation-
al Journal of 
Obesity 
UK European 
Prospective 
Investigati-
on Into 
Cancer and 
Nutrition-
Norfolk 
study 
Prospective 
cohort 
1993-2006 20,608 357 Height (per 10cm 
increase) 
  age, sex, smoking, alcohol, 
education, exercise, family 
history of CRC, energy 
intake, folate, fiber, total 
meat, processed meat, waist 
circumference 
colorectal cancer 1.23 (0.92-1.65) 1.42 (1.04-1.93) 
Brandstedt 
et al., 2012 
(87) 
Biology of 
Sex 
Differences  
Sweden Malmo Diet 
and Cancer 
Study 
Prospective 
cohort 
1991-2009 28,098 584 Height (largest 
quartile vs. smallest 
quartile) 
    age at baseline, education, 
smoking habits, alcohol 
colorectal cancer 1.28 (0.90-1.82) 1.29 (0.89-1.85) 
colon cancer 1.52 (0.96-2.42) 1.33 (0.83-2.12) 
rectal cancer 1.03 (0.59-1.80) 1.18 (0.63-2.21) 
Shin et al., 
2011 
(88) 
PLoS ONE Korea Korean 
National 
Health 
System 
Prospective 
cohort 
1996-2003 1,265,226 4,144 Height (largest 
quartile vs. smallest 
quartile) 
   age 
proximal colon 
cancer 
1.10 (0.80-1.40) 1.20 (0.80-1.90) 
distal colon cancer 1.30 (1.10-1.60) 1.30 (0.90-2.10) 
rectal cancer 1.10 (1.00-1.30) 1.50 (1.10-2.00) 
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Table 3 (continued) 
Author, 
Year 
Journal Country Database Study type Study period 
(recruitment 
to follow-up) 
Sample size 
(after 
exclusions) 
Colorectal 
cancer 
cases 
Exposure/ 
Outcome 
Relative risk (95% CI) Confounders adjusted 
for 
Males Females 
Green et 
al., 2011 
(79) 
Lancet UK Million 
Women 
Study 
Prospective 
cohort 
1996-2008 1,297,124 9,471 Height (10cm 
increase) 
    age, region, SES, smoking, 
alcohol intake, BMI, strenuous 
exercise, age at menarche, 
parity, age at first birth  
colon cancer   1.25 (1.17-1.32) 
rectal cancer   1.14 (1.05-1.24) 
Oxentenko 
et al., 
2010 
(80) 
Cancer 
Prevention 
Research 
USA Iowa 
Women's 
Health Study 
Prospective 
cohort 
1986-2005 36,941 1,464 Height (largest 
quartile vs. 
smallest quartile) 
   age at baseline, age at 
menopause, exogenous 
estrogen use, oral 
contraceptive use, smoking 
status, cigarette pack-years, 
physical activity level, self-
reported diabetes mellitus, and 
intake of total energy, total fat, 
red meat, fruits and 
vegetables, calcium, folate, 
vitamin E, and alcohol.  
colorectal cancer  1.38 (1.17-1.64) 
Lundqvist 
et al., 
2007 
(84) 
Internati-
onal Journal 
of Cancer 
Sweden, 
Finland 
 Prospective 
co-twin 
control 
1961-2004 68,375 837 Height (per 1 
standard 
deviation 
increase) 
Males and females combined 
  
smoking, physical activity 
during leisure time, 
educational level, diabetes 
colon cancer 1.00 (0.82-1.22) 
rectal cancer 1.04 (0.81-1.34) 
Pischon et 
al., 2006 
(52) 
Journal of 
the National 
Cancer 
Institute 
 
Europe European 
Prospective 
Investigation 
Into Cancer 
and 
Nutrition 
Prospective 
cohort 
1992-2004 368,277 1,570 Height (largest 
quartile vs. 
smallest quartile) 
   center, age at recruitment, 
smoking status, education, 
alcohol intake, physical 
activity, fiber intake, 
consumption of red and 
processed meat, fish and 
shellfish, fruits, vegetables 
colon cancer 1.40 (0.99-1.98) 1.79 (1.30-2.46) 
rectal cancer 1.00 (0.66-1.52) 0.78 (0.50-1.21) 
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Table 3 (continued) 
Author, 
Year 
Journal Country Database Study type Study period 
(recruitment 
to follow-up) 
Sample size 
(after 
exclusions) 
Number of 
colorectal 
cancer 
cases 
Exposure/ 
Outcome 
Relative risk (95% CI) Confounders 
adjusted for 
Males Females 
Bowers et 
al., 2006 
(85) 
American 
Journal of 
Epide-
miology  
Finland Alpha-
Tocopherol, 
Beta-
Carotene 
Cancer 
Prevention 
Study 
Prospective 
cohort 
1985-2002 29,133 410 Height (largest 
quintile vs. 
smallest quintile) 
    age, number of cigarettes 
smoked per day, weight  
 colorectal cancer 0.90 (0.64-1.27)   
colon cancer 0.82 (0.78-1.53)   
rectal cancer 1.02 (0.61-1.70)   
Otani et 
al., 2005 
(86) 
Cancer 
Causes and 
Control 
Japan Japan Public 
Health 
Centre-
based 
Prospective 
Study 
Prospective 
cohort 
1990-2001 102, 949 986 Height (largest 
quintile vs. 
smallest quintile) 
   age, Public Health Center 
areas, smoking, alcohol 
consumption, weight 
 colorectal cancer 1.10 (0.80-1.50) 1.10 (0.70-1.60) 
    
Engeland 
et al., 
2005 
(83) 
Cancer 
Causes and 
Control 
Norway   Prospective 
cohort 
1963-2002 2,001,698 47,117 Height (per 10cm 
increase) 
    age at measurement, year 
of birth, BMI 
colorectal cancer 1.14 (1.11.-1.16) 1.17 (1.14-1.20) 
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5.1.2. Body Mass Index and colorectal cancer incidence 
The individual studies that explored the association between BMI and the risk of 
developing colon cancer, rectal cancer or CRC were reviewed and summarized in 
this section. 
 
Pubmed was used to search for studies on the link between BMI and CRC risk. 
Search for literature was conducted in 2014 and updated in 2016. It included the 
following search string: body and mass and index and (colon or rectal or colorectal) 
and cancer and (risk or incidence). Through Pubmed, 1710 papers were found, and 
56 papers met the inclusion criteria. The search strategy is detailed in Figure 10. 
These papers were published between 1985 and 2016. 
 
Table 4 summarizes 14 of the most recent studies on the association between BMI 
and CRC incidence. These papers were published between 2011 and 2016 and 
examined the association in various countries within Europe, Eastern Mediterranean, 
North America and Asia. The sample size of the databases that these papers used to 
examine the association between BMI and CRC incidence varied from 11,000 to five 
million.  
 
Figure 10 Flowchart of the search strategy for studies on the association between 
Body Mass Index and colorectal cancer risk 
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Table 4 Summary of the individual studies that explored the association between Body Mass Index and colorectal cancer incidence 
Author, 
Year 
Journal Country Database  Study type Study period 
(recruitment 
to follow-up) 
Sample size 
(after 
exclusions) 
Colorecta
l cancer 
cases 
Exposure/ 
Outcome 
Relative risk (95% CI) Confounders adjusted for 
Males Females 
Kantor 
et al., 
2016 
(111) 
British 
Medical 
Journal 
Sweden   Prospective 
cohort 
1969-2010 239,658 885 BMI at age 16-20 
(obese vs. normal) 
    age at conscription, erythrocyte 
sedimentation rate, erythrocyte 
volume fraction, BMI, household 
crowding, health status; systolic blood 
pressure, diastolic blood pressure, 
muscular strength, physical working 
capacity, cognitive function  
colorectal cancer 2.38 (1.51-3.76)   
colon cancer 2.55 (1.41-4.61)   
rectal cancer 2.17 (1.05-4.46)   
Zhang et 
al., 2015 
(97) 
Cancer, 
Epidemi-
ology, 
Biomarkers 
& 
Prevention 
USA Nurses' 
Health 
Study and 
Health 
Professio-
nals 
Follow-up 
Study 
Prospective 
cohort 
1976-2010 109,771 2,100 BMI at age 21 for 
males and 18 for 
females (largest 
sextile vs. smallest 
sextile) 
   age, adult BMI, height, pack-years of 
smoking before age 30, history of 
CRC in a parent or sibling, history of 
sigmoidoscopy/endoscopy, current 
physical activity, regular aspirin use, 
multivitamin use, alcohol 
consumption, current energy-adjusted 
total intake of calcium, vitamin D, 
folate, red meat, processed meat, and 
postmenopausal hormone use 
(females only)  
colorectal cancer 1.18 (0.84-1.65) 1.44 (1.06-1.95) 
Kabat et 
al., 2015 
(95) 
Cancer 
Causes and 
Control 
USA Women's 
Health 
Initiative 
Prospective 
cohort 
1993-2013 143,901 1,908 BMI at age 
(baseline) 50-79 
(largest quintile 
vs. smallest 
quintile) 
    age, alcohol, smoking, hormone 
therapy, MET-hours/week, aspirin 
intake, diabetes, family history of 
CRC in a first-degree relative, 
education, ethnicity, treatment 
allocation  colorectal cancer   1.44 (1.23-1.68) 
Han et 
al., 2014 
(96) 
Internation-
al Journal of 
Cancer 
USA Atherosc-
lerosis 
Risk in 
Communit
ies  
Prospective 
cohort 
1987-2009 13,901 198 BMI at age 25 
(obese vs. normal) 
   race- center, age and height at 
baseline, education, cigarette smoking 
status at age 25, and age at menarche, 
cigarette smoking, alcohol 
consumption and physical activity at 
baseline, menopause status 
colorectal cancer 1.54 (0.84-2.81) 0.91 (0.37-2.25) 
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Table 4 (continued) 
Author, 
Year 
Journal Country Database  Study type Study period 
(recruitment 
to follow-up) 
Sample size 
(after 
exclusions) 
Colorectal 
cancer 
cases 
Exposure/ Outcome Relative risk (95% CI) Confounders adjusted 
for 
Males Females 
Bhaskaran 
et al., 2014 
(112) 
Lancet UK Clinical 
Practice 
Research 
Datalink 
Prospective 
cohort 
1987-2012 5,243,978 19,588 BMI at (baseline) 
median age 37.9 (per 5 
kg/m2) 
Males and females combined 
 
age, diabetes status, 
smoking, alcohol use, SES, 
calendar year    
 
colon cancer 1.10 (1.07-1.13) 
rectal cancer 1.04 (1.00-1.08) 
Poynter et 
al., 2013 
(94) 
Cancer, 
Epidemi-
ology, 
Biomark-
ers & 
Preventi-
on 
USA Iowa 
Women's 
Health 
Study 
Prospective 
cohort 
1986-2008 37,459 1,626 BMI at age (baseline) 
55-71 (obese vs. 
normal) 
 
Younger age 
band * 
age at baseline, BMI, 
physical activity level, 
smoking, estrogen use  
 
colon cancer  1.44 (1.16-1.78) 
BMI at age (baseline) 
55-71 (obese vs. 
normal) 
 
Older age band 
colon cancer  1.38 (1.13-1.69) 
Li et al., 
2013 
(89) 
Internati-
onal 
Journal of 
Obesity 
(London) 
China Shanghai 
Men's 
Health 
Study and 
Shanghai 
Women's 
Health 
Study 
Prospective 
cohort 
1997-2009 134,255 935 BMI at age 20 (highest 
quintile vs. lowest 
quintile) 
    age at baseline, education, 
income, cigarette use, 
alcohol consumption, tea 
consumption, physical 
activity, family history of 
CRC, menopausal status and 
intakes of total energy, red 
meat, fruits and vegetables  
 
colorectal cancer 1.21 (0.81-1.79) 1.08 (0.81-1.44) 
colon cancer 1.38 (0.81-2.36) 1.06 (0.73-1.54) 
rectal cancer 1.02 (0.57-1.84) 1.11 (0.70-1.75) 
BMI at age 40 for males 
and 50  for females 
(highest quintile vs. 
lowest quintile) 
    
colorectal cancer 1.61 (1.12-2.31) 1.19 (0.87-1.63) 
colon cancer 2.01 (1.24-3.24) 1.18 (0.80-1.74) 
rectal cancer 1.18 (0.67-2.07) 1.20 (0.72-2.03) 
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Table 4 (continued) 
Author, 
Year 
Journal Country Database  Study type Study period 
(recruitment 
to follow-up) 
Sample 
size (after 
exclusions) 
Colorectal 
cancer 
cases 
Exposure/ 
Outcome 
Relative risk (95% CI) Confounders adjusted 
for 
Males Females 
Kitahara 
et al., 
2013 
(90) 
Journal 
of 
Clinical 
Oncol-
ogy 
USA Prostate, Lung, 
Colorectal and 
Ovarian Cancer 
Screening Trial 
Prospective 
cohort 
1993-2009 74,474 966 BMI at age (baseline) 
50-74 (obese vs. 
normal) 
    age at baseline, study center; 
screening adequacy and 
results before colorectal 
cancer diagnosis, 
race/ethnicity, smoking status, 
and menopausal hormone 
therapy use 
colorectal cancer 1.48 (1.16-1.89) 1.03 (0.80-1.33) 
Kabat et 
al., 2013 
(113) 
Cancer 
Causes 
and 
Control 
USA Women's 
Health 
Initiative 
Prospective 
cohort 
1993-2011 11,124 169 BMI at age (baseline) 
50-79 (highest quartile 
vs. lowest quartile) 
   age at enrollment, education, 
ethnicity, family history of 
CRC, hormone therapy, 
physical activity, pack-years 
of smoking, alcohol intake, 
history of diabetes, intake of 
energy, randomization status  
colorectal cancer  1.07 (0.66-1.75) 
Renehan 
et al., 
2012 
(102) 
Ameri-
can 
Journal 
of  
Epide-
miology 
USA National 
Institutes of 
Health-AARP 
Diet and Health 
Study 
Prospective 
cohort 
1995-2006 273,679 4076 BMI at age 18 (per 5 
kg/m2) 
    age, race/ethnicity, 
educational, physical activity, 
smoking status, alcohol 
consumption, menopausal 
hormone therapy use (females 
only) 
colon cancer 1.10 (1.00-1.20) 1.11 (0.96-1.29) 
rectal cancer 1.01 (0.86-1.18) 0.89 (0.66-1.21) 
BMI at age 50 (per 5 
kg/m2) 
    
colon cancer 1.18 (1.10-1.26) 1.13 (1.05-1.23) 
rectal cancer 1.07 (0.96-1.19) 1.00 (0.85-1.16) 
Park et 
al., 2012 
(44) 
Interna-
tional 
Journal 
of 
Obesity 
UK European 
Prospective 
Investigation 
Into Cancer and 
Nutrition-
Norfolk study 
Prospective 
cohort 
1993-2006 20,608 357 Measured BMI at age 
(baseline) 39-79 (per 4 
kg/m2) 
  age, sex, smoking, alcohol, 
education, exercise, family 
history of CRC, energy intake, 
folate, fiber, total meat and 
processed meat, intakes, waist 
and hip circumference 
 
colorectal cancer 0.86 (0.60-1.24) 0.84 (0.58-1.19) 
Self-reported BMI at 
age (baseline) 39-79 
(per 4 kg/m2) 
   
colorectal cancer 0.97 (0.70-1.34) 1.16 (0.90-.51) 
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Table 4 (continued) 
Author, 
Year 
Journal Country Database Study type Study period 
(recruitment 
to follow-up) 
Sample size 
(after 
exclusions) 
Colorectal 
cancer 
cases 
Exposure/ 
Outcome 
Relative risk, RR (95% CI) Confounders 
adjusted for 
Males Females 
Matsuo 
et al., 
2011 
(108) 
Annals of 
Oncology 
Japan Japan Public Health 
Centre-based 
Prospective Study I 
and II, Japan 
Collaborative 
Cohort Study, 
Miyagi Cohort 
Study, Three-
Prefecture Cohort 
Study in Miyagi, 
Takayama Study, 
Ohsaki Cohort 
Study 
Population-
based cohort  
1958-2006 341,384 4,979 BMI at age 
(baseline) 35-103 
(per 1 kg/m2) 
  age, area, smoking, 
drinking 
 colorectal cancer 1.03 (1.02-1.04) 1.02 (1.00-1.03) 
colon cancer 1.04 (1.02-1.06) 1.04 (1.03-1.06) 
rectal cancer 1.02 (1.00-1.04) 1.00 (0.99-1.00) 
Odegaard 
et al., 
2011 
(93) 
Cancer Singapore The Singapore 
Chinese Health 
Study 
Prospective 
cohort 
1993-2007 51,251 980 BMI at age 
(baseline) 45-74 
(>27.5 kg/m2 vs 
21.5-24.4 kg/m2 ) 
Males and females combined age, sex, year of 
enrollment, dialect, 
education, diabetes 
status, familial history 
of cancer, smoking, 
alcohol intake, dietary 
pattern score, physical 
activity, sleep, energy 
intake 
colorectal cancer 1.25 (1.01-1.55) 
colon cancer 1.48 (1.13-1.92) 
rectal cancer 0.93 (0.64-1.36) 
Levi et 
al., 2011 
(114) 
Cancer, 
Epidem-
iology, 
Biomar-
kers & 
Prevention 
Israel   Prospective 
cohort 
1967-2006 1,109,864 638 BMI at age 
(baseline) 16-19 
(highest quintile 
vs. lowest 
quintile) 
   year of birth, age at 
BMI, country of 
origin, residence, 
immigration status, 
SES, and height 
colon cancer 1.69 (1.24-2.29)   
rectal cancer 0.86  (0.54-1.34)   
* Younger age band include female participants who were diagnosed with colorectal cancer, died or were lost to follow-up before the age of 75 years. Otherwise, participants were placed in the older age band. 
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5.2. Questions and options in the CLEAR Study 
 
The data used in this current study comes from the CLEAR Study. An overview of 
the CLEAR Study is given in Section 1.7. Information relevant to this current study 
is given in Section 2. The specific details of the questions and options, as found in 
the CLEAR Study, that were used in this current study are described in this Section. 
 
5.2.1. Definition of cases and controls 
Participants in the CLEAR Study were asked to select one of two responses: 
(A) I have been diagnosed with cancer in the last 18 months.  
(B) I have never been diagnosed with cancer.  
5.2.2. Height 
Height was based on the following CLEAR Study question: 
How tall are you without shoes? (please give to the nearest cm or inch). 
 
5.2.3. Body Mass Index 
Participants were asked to recall weight from two points in time in the following 
CLEAR Study questions: 
(C) About how much did you weigh before you, or your partner, became ill? 
(D) About how much did you weigh when you were 20 years old? 
5.2.4. Proxies of obesity 
Information used to create the proxies of obesity was based on responses to the 
following CLEAR Study questions: 
 
(E) In your 20’s and 30’s, if you gained weight, where did you mostly put it on?  
(F) After age 50, if you gained weight, where did you mostly tend to put it on? 
Participants could select one or more of the following options, which were 
provided for each question: 
1. Neck 
2. Arms 
3. Chest 
4. Waist/Abdomen 
5. Hips 
6. Thighs 
7. Buttocks 
8. You didn’t gain weight 
 
 
60 
9. Other, please specify 
Participants who chose Other, please specify could specify a region of the body in a 
comment section. 
 
5.2.5. Education 
Education was based on the following CLEAR Study question: 
 
What is the highest qualification you have completed? 
 
Participants could choose one of the six options listed below. Each option defined a 
category for the covariate, Education. 
 
1. No school certificate or other qualifications 
2. School or intermediate certificate (Yr 10 or equivalent) 
3. Higher School or leaving certificate (Yr 12 or equivalent) 
4. Trade/Apprenticeship (e.g. hairdresser, chef) 
5. Certificate/Diploma (e.g. child care, technician) 
6. University degree or higher 
5.2.6. Household income 
Household income was based on the following CLEAR Study question: 
 
Just before you, or your partner, became ill, what was your usual yearly 
HOUSEHOLD income before tax, from all sources? (please include benefits, 
pensions, superannuation etc)  
 
Participants could choose one of the eight options listed below. 
1. Less than $10,000 per year 
2. $10,000-$25,000 per year 
3. $25,000-$50,000 per year 
4. $50,000-$75,000 per year 
5. $75,000-$100,000 per year 
6. $100,000-$125,000 per year 
7. More than $125,000 per year 
8. I would prefer not to answer question 81 
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5.2.7. Alcohol consumption 
Alcohol consumption in the CLEAR Study was based on the answers to the 
following question: 
 
Just before you, or your partner, became ill, about how many alcoholic drinks did 
you have each week? (one drink = a glass of wine, middy of beer or nip of spirits) 
 
5.2.8. Smoking status 
Smoking status in the CLEAR Study was based on the answers to the following 
questions: 
 
(G) Have you ever been a regular smoker? 
(H) If yes, how old were you when you started smoking regularly? 
(I) Just before you, or your partner, became ill, were you a regular smoker? 
(J) If yes, are you still a regular smoker? 
(K) If no, how old were you when you stopped smoking regularly? 
5.2.9. Physical activity 
Participants were asked in the CLEAR Study about the number of sessions of 
vigorous activity undertaken in a week as follows: 
 
Just before you or your partner, became ill, in a NORMAL week, how many times did 
you engage in VIGOROUS exercise lasting for 20 minutes or more? (exercise which 
makes you breathe harder or puff and pant, such as netball, squash, jogging, 
aerobics, vigorous swimming, etc.) 
 
Participants were asked in the CLEAR Study about the number of sessions of less 
vigorous activity undertaken in a week as follows: 
 
Just before you, or your partner, became ill, in a NORMAL week, how many times 
did you engage in LESS VIGOROUS exercise lasting 20 minutes or more? (exercise 
which does not make you breathe harder or puff and pant such as walking, 
gardening, swimming, lawnbowls, etc.) 
(please cross (X) one only) 
 
For each of the two questions, participants could select one of the following 
responses: 
 
1. Never 
2. Once a week 
3. Two or three times a week 
4. Four, five or six times a week 
5. Once every day 
6. More than once every day. 
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5.3. Approach to develop the Proxies of obesity 
 
5.3.1. Correlation between individual body regions 
Tables 5 and 6 show the correlation between the individual body regions where 
participants gained the most weight, separately for their 20's and 30's and after the 
age of 50. At both time points, if an individual had gained weight in the arms, they 
were likely to have also gained weight in the neck, as arms and neck were highly 
correlated. The following regions were also highly correlated at the two-time points, 
chest and arms, thighs and hips, buttocks and hips, and buttocks and thighs. At both 
time points, weight gain in the waist was not correlated with any other regions.  
 
 
Table 5 During the 20’s and 30’s, the polychoric correlation between the individual 
body regions where participants gained the most weight 
  Neck Arms Chest Waist Hips Thighs Buttocks 
Neck 1.00 0.63 0.57 0.42 0.23 0.30 0.25 
Arms  1.00 0.74 0.13 0.36 0.52 0.40 
Chest   1.00 0.28 0.19 0.28 0.17 
Waist    1.00 0.007 -0.07 0.001 
Hips     1.00 0.81 0.75 
Thighs      1.00 0.84 
Buttocks       1.00 
 
Table 6 After the age of 50, the polychoric correlation between the individual body 
regions where participants gained the most weight 
  Neck Arms Chest Waist Hips Thighs Buttocks 
Neck 1.00 0.62 0.55 0.44 0.28 0.28 0.31 
Arms  1.00 0.66 0.27 0.57 0.59 0.56 
Chest   1.00 0.40 0.35 0.36 0.37 
Waist    1.00 0.03 0.02 0.09 
Hips     1.00 0.86 0.79 
Thighs      1.00 0.87 
Buttocks       1.00 
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5.3.2. Association between Body Mass Index and the Proxies of 
obesity 
 
Within controls, BMI was compared to the three proxies of obesity, separately for 
the sexes. The aim of this comparison was to examine whether information on 
participant’s experience of weight gain, measured by the proxies of obesity, was in 
line with their experience of obesity, measured by BMI. 
 
BMI was compared to the three proxies of obesity measured for their 20’s and 30’s 
(Table 7). In both sexes, being overweight or obese at the age of 20 or just before 
diagnosis corresponded to having experienced weight gain or weight gain in the 
waist during their 20’s and 30’s. In both sexes, having a normal BMI at the age of 20 
or just before diagnosis corresponded to having experienced weight gain in the apple 
region during their 20’s and 30’s.  
 
Again, BMI was compared to the three proxies of obesity measured for after the age 
of 50 (Table 8). In both sexes, being overweight or obese just before diagnosis 
corresponded to having experienced weight gain after the age of 50. Male controls 
who had a normal BMI or female controls who were overweight or obese just before 
diagnosis were more likely to have experienced weight gain in the waist after the age 
of 50. In both sexes, having a normal BMI just before diagnosis corresponded to 
having experienced weight gain in the apple region after the age of 50. However, in 
both sexes, BMI at the age of 20 was not associated with having experienced weight 
gain, weight gain in the waist or the apple region after the age of 50. 
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Table 7 In controls, Body Mass Index compared to the proxies of obesity measured for the 20’s and 30’s (weight gain, WG20; weight gain 
in the waist, WGW20; and weight gain in the apple region, WGA20) 
 Males  Females 
  WG20 WGW20 WGA20  WG20 WGW20 WGA20 
 
No, % Yes, % No, % Yes, % No, % Yes, % 
 
No, % Yes, % No, % Yes, % No, % Yes, % 
  N=168 N=713 N=48 N=665 N=160 N=553  N=142 N=796 N=229 N=567 N=540 N=256 
BMI categories at the age 
of 20 (kg/m2)       
       
10 to <25 85.7 69.7 79.2 69.0 67.5 70.3  97.2 84.7 86.0 84.1 83.9 86.3 
25 to <30 10.7 26.1 18.8 26.6 28.8 25.3  2.1 11.9 11.4 12.2 12.8 10.2 
30 to 70 3.6 4.2 2.1 4.4 3.8 4.3  0.7 3.4 2.6 3.7 3.3 3.5 
p-value <0.0001 a 0.0003 b 0.0006 c  0.0003 a 0.002 b 0.002 c 
BMI just before diagnosis 
categories (kg/m2)       
 
      
10 to <25 54.8 25.0 33.3 24.4 24.4 25.1  63.4 42.5 48.5 40.0 41.3 44.9 
25 to <30 38.7 49.5 52.1 49.3 50.0 49.4  28.9 32.7 28.8 34.2 32.0 34.0 
30 to 70 6.5 25.5 14.6 26.3 25.6 25.5  7.7 24.9 22.7 25.7 26.7 21.1 
p-value <0.0001 a <0.0001 b <0.0001 c 
 
<0.0001 a <0.0001 b <0.0001 c  
a p-value for the association between BMI and WG 
b p-value for the association between BMI and WGW 
c p-value for the association between BMI and WGA 
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Table 8 In controls, Body Mass Index compared to the proxies of obesity measured for after age 50 (weight gain, WG50; weight gain in the 
waist, WGW50; and weight gain in the apple region, WGA50) 
 Males  Females 
  WG50 WGW50 WGA50  WG50 WGW50 WGA50 
 
No, % Yes, % No, % Yes, % No, % Yes, % 
 
No, % Yes, % No, % Yes, % No, % Yes, % 
  N=80 N=605 N=9 N=596 N=76 N=529  N=63 N=726 N=97 N=629 N=450 N=276 
BMI categories at the age 
of 20 (kg/m2)       
       
10 to <25 76.3 75.5 44.4 76.0 68.4 76.6  85.7 87.1 84.5 87.4 85.6 89.5 
25 to <30 18.8 21.3 55.6 20.8 28.9 20.2  11.1 10.5 12.4 10.2 11.3 9.1 
30 to 70 5.0 3.1 0.0 3.2 2.6 3.2  3.2 2.5 3.1 2.4 3.1 1.4 
p-value 0.6a 0.1b 0.4c  0.9a 0.9b 0.5c 
BMI just before diagnosis 
categories (kg/m2)       
 
      
10 to <25 63.8 25.6 22.2 25.7 14.5 27.2  69.8 40.2 50.5 38.6 35.6 47.8 
25 to <30 31.3 51.6 55.6 51.5 51.3 51.6  22.2 33.9 25.8 35.1 34.0 33.7 
30 to 70 5.0 22.8 22.2 22.8 34.2 21.2  7.9 25.9 23.7 26.2 30.4 18.5 
p-value <0.0001 a <0.0001 b <0.0001 c 
 
<0.0001 a <0.0001 b <0.0001 c  
a p-value for the association between BMI and WG 
b p-value for the association between BMI and WGW 
c p-value for the association between BMI and WGA 
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5.3.3. Missing data for the Proxies of obesity 
 
Table 9 Body Mass Index distributions of males who with missing/invalid information (i.e. Missing) compared to males with information (i.e. 
Respondents) on weight gain after the age of 50 (WG50). 
  Cases   Controls 
 Missing, n % Respondents, n %  Missing, n % Respondents, n % 
  N=68 100.0 N=415 100.0   N=222 100.0 N=685 100.0 
BMI categories at the age of 20 (kg/m2)             
 10 to <25 45 66.2 284 68.4  145 65.3 518 75.6 
25 to <30 19 27.9 108 26.0  63 28.4 144 21.0 
30 to 70 4 5.9 23 5.5  14 6.3 23 3.4 
p-heterogeneity 0.9  0.007 
BMI just before diagnosis categories (kg/m2)              
10 to <25 21 30.9 95 22.9  76 34.2 206 30.1 
25 to <30 35 51.5 182 43.9  93 41.9 337 49.2 
30 to 70 12 17.6 138 33.3  53 23.9 142 20.7 
p-heterogeneity 0.03   0.2 
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Table 10 Body Mass Index distributions of females who with missing/invalid information (i.e. Missing) compared to females with information 
(i.e. Respondents) on weight gain after the age of 50 (WG50). 
  Cases   Controls 
 Missing, n % Respondents, n %  Missing, n % Respondents, n % 
  N=72 100.0 N=301 100.0   N=176 100.0 N=789 100.0 
BMI categories at the age of 20 (kg/m2)             
 10 to <25 61 84.7 268 89.0  150 85.2 686 86.9 
25 to <30 7 9.7 30 10.0  18 10.2 83 10.5 
30 to 70 4 5.6 3 1.0  8 4.5 20 2.5 
p-heterogeneity 0.04  0.4 
BMI just before diagnosis categories (kg/m2)            
 
 
10 to <25 36 50.0 127 42.2  101 57.4 336 42.6 
25 to <30 23 31.9 100 33.2  53 30.1 260 33.0 
30 to 70 13 18.1 74 24.6  22 12.5 193 24.5 
p-heterogeneity 0.4   0.0003 
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